Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines

BACKGROUND OF THE INVENTION

In the 1950's the 1H-imidazo[4,5-c]quinoline ring system was developed, and 1-(6-methoxy-8-quinolinyl)-2-methyl-1H-imidazo[4,5-c]quinoline was synthesized for possible use as an antimalarial agent. Subsequently, syntheses of various substituted 1H-imidazo[4,5-c]quinolines were reported. For example, 1-[2-(4-piperidyl)ethyl]-1H-imidazo[4,5-c]quinoline was synthesized as a possible anticonvulsant and cardiovascular agent. Also, several 2-oxoimidazo[4,5-c]quinolines have been reported.

Certain 1H-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. Subsequently, certain substituted 1H-imidazo[4,5-c]pyridin-4-amine, quinolin-4-amine, tetrahydroquinolin-4-amine, naphthyridin-4-amine, and tetrahydronaphthyridin-4-amine compounds as well as certain analogous thiazolo and oxazolo compounds were synthesized and found to be useful as immune response modifiers, rendering them useful in the treatment of a variety of disorders.

But despite important progress in the effort to find immunomodulating compounds, there is still a critical scientific and medical need for additional compounds that have an ability to modulate aspects of the immune response, by induction of cytokine biosynthesis or other mechanisms.

SUMMARY OF THE INVENTION

The present invention provides a new class of compounds that are useful in modulating cytokine biosynthesis in animals. In one aspect, the present invention provides compounds of the Formula I:

embedded image

wherein:

R_Aand R_Btaken together form a fused benzene ring or fused pyridine ring wherein the benzene ring or pyridine ring is substituted by one R₃group, or substituted by one R₃group and one R group; and

R₃is selected from the group consisting of:

- —O—Z—Ar,
- —O—Z—Ar′—Y—R₄,
- —O—Z—Ar′—X—Y—R₄,
- —O—Z—Ar′—R₅, and
  
  wherein R, R₂, Z, Ar, Ar′, X, Y, R₄, and R₅are as defined below;
  
  and pharmaceutically acceptable salts thereof.

The compounds of Formula I are useful, for example, as immune response modifiers (IRMs) due to their ability to modulate cytokine biosynthesis (e.g., induce or inhibit the biosynthesis or production of one or more cytokines) and otherwise modulate the immune response when administered to animals. Compounds can be tested, for example, using the test procedures described in the Examples Section. Compounds can be tested for induction of cytokine biosynthesis by incubating human PBMC in a culture with the compound(s) at a concentration range of 30 to 0.014 μM and analyzing for interferon (α) or tumor necrosis factor (α) in the culture supernatant. Compounds can be tested for inhibition of cytokine biosynthesis by incubating mouse macrophage cell line Raw 264.7 in a culture with the compound(s) at a single concentration of, for example, 5 μM and analyzing for tumor necrosis factor (α) in the culture supernatant. The ability to modulate cytokine biosynthesis, for example, induce the biosynthesis of one or more cytokines, makes the compounds useful in the treatment of a variety of conditions such as viral diseases and neoplastic diseases, that are responsive to such changes in the immune response.

In another aspect, the present invention provides pharmaceutical compositions containing an effective amount of a compound of Formula I, and methods of inducing cytokine biosynthesis in animal cells, treating a viral disease in an animal, and/or treating a neoplastic disease in an animal by administering to the animal an effective amount of a compound of Formula I and/or a pharmaceutically acceptable salt thereof.

In another aspect, the invention provides methods of synthesizing the compounds of Formula I and intermediates useful in the synthesis of these compounds.

As used herein, “a,” “an,” “the,” “at least one,” and “one or more” are used interchangeably.

The terms “comprising” and variations thereof do not have a limiting meaning where these terms appear in the description and claims.

The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. Guidance is also provided herein through lists of examples, which can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive or exhaustive list.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS OF THE INVENTION

The present invention provides compounds of the following Formula (I):

embedded image

as well as more specific compounds of the following Formulas (II, III, IV, V, VI, IIIa, IVa, VIa, and VII):

embedded image

wherein R_A, R_B, R, R₂, R₃, G, and n are as defined below, and pharmaceutically acceptable salts thereof.

For any of the compounds presented herein, each one of the following variables (e.g., A, X, Y, Z, R_A, R_B, R, R₂, R₃, Q, G, n, and so on) in any of its embodiments can be combined with any one or more of the other variables in any of their embodiments and associated with any one of the formulas described herein, as would be understood by one of skill in the art. Each of the resulting combinations of variables is an embodiment of the present invention.

In some embodiments, R_Aand R_Btaken together form a fused benzene ring or fused pyridine ring wherein the benzene ring or pyridine ring is substituted by one R₃group, or substituted by one R₃group and one R group. In some embodiments, R₃is attached at the 7-position.

In some embodiments, R is selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, and trifluoromethyl.

In some embodiments, R₂is selected from the group consisting of hydrogen, alkyl, hydroxyalkylenyl, haloalkylenyl, alkenyl, alkyl-O-alkylenyl, alkyl-O-alkenylenyl, alkenyl-O-alkylenyl, alkenyl-O-alkenylenyl, N(R₈)₂-alkylenyl, N₃-alkylenyl, N(R₈)₂—C(O)—O-alkylenyl, heterocyclyl, heterocyclyl-O-alkylenyl, heterocyclyl-O-alkenylenyl, aryl, aryl-O-alkylenyl, aryl-O-alkenylenyl, heteroaryl, heteroaryl-O-alkylenyl, and heteroaryl-O-alkenylenyl.

In some embodiments, R₂is selected from the group consisting of hydrogen, C_1-8alkyl, and C_1-8alkyl-O—C_1-8alkylenyl. In some embodiments, R₂is hydrogen, C_1-4alkyl, or C_1-4alkyl-O—C_1-4alkylenyl. In some embodiments, R₂is methyl, ethyl, n-propyl, n-butyl, 2-methoxyethyl, methoxymethyl, or ethoxymethyl.

In some embodiments, R₃is selected from the group consisting of —O—Z—Ar, —O—Z—Ar′-R₅, and —O—Z—Ar′—X—R₅. In some embodiments, R₃is —O—Z—Ar′—Y—R₄, —O—Z—Ar—X—Y—R₄, or —O—Z—Ar′—R₅. In some embodiments, R₃is In some embodiments, R₃is —O—Z—Ar.

In some embodiments, R₄is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo. In some embodiments, R₄is selected from the group consisting of hydrogen, alkyl, aryl, arylalkylenyl, heteroaryl, and heteroarylalkylenyl. In some embodiments, R₄is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and heterocyclyl. In some embodiments, R₄is selected from the group consisting of alkyl, aryl, heteroaryl, heteroarylalkylenyl, and heterocyclyl. In some embodiments, R₄is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl.

In some embodiments, R₅is selected from the group consisting of

embedded image

In some embodiments, R₅is

embedded image

In some embodiments, R₆is selected from the group consisting of ═O and ═S.

In some embodiments, R₇is C_2-7alkylene.

In some embodiments, R₈is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl. In some embodiments, R₈is selected from the group consisting of hydrogen, C_1-4alkyl, and alkoxyalkylenyl.

In some embodiments, R₉is selected from the group consisting of hydrogen and alkyl.

In some embodiments, R₁₀is C_3-8alkylene.

In some embodiments, Ar is selected from the group consisting of aryl and heteroaryl both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, heterocyclylalkylene, amino, alkylamino, and dialkylamino.

In some embodiments, particularly when R₃is —O—Z—Ar, Ar is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrrolyl, thienyl, furyl, isoxazolyl, thiazolyl, imidazolyl, benzimidazolyl, 1,2,3-triazolyl, indolyl, benzothiazolyl, and oxazolyl; each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, trifluoromethoxy, aryl, and hydroxyalkyl. In some embodiments, Ar is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrrolyl, thienyl, furyl, isoxazolyl, thiazolyl, and imidazolyl; each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, trifluoromethyl, and trifluoromethoxy. In some embodiments, Ar is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrrolyl, thienyl, furyl, isoxazolyl, thiazolyl, and imidazolyl; each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, and trifluoromethoxy. In some embodiments, Ar is phenyl substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, trifluoromethyl, and trifluoromethoxy. In some embodiments, Ar is phenyl substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, and trifluoromethoxy.

In some embodiments, Ar′ is selected from the group consisting of arylene and heteroarylene both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, and dialkylamino. In some embodiments, Ar′ is phenylene, naphthylene, pyridylene, pyrrolylene, thienylene, or furylene. In some embodiments, Ar′ is phenylene.

In some embodiments, A is selected from the group consisting of —O—, —C(O)—, —S(O)_0-2—, —CH₂—, and —N(R₄)—.

In some embodiments, Q is selected from the group consisting of a bond, —C(R₆)—, —C(R₆)—C(R₆)—, —S(O)₂—, —C(R₆)—N(R₈)—W—, —S(O)₂—N(R₈)—, —C(R₆)—O—, and —C(R₆)—N(OR₉)—. In some embodiments, Q is selected from the group consisting of a bond, —C(O)—, —S(O)₂—, and —C(R₆)—N(R₈)—.

In some embodiments, V is selected from the group consisting of —C(R₆)—, —O—C(R₆)—, —N(R₈)—C(R₆)—, and —S(O)₂—.

In some embodiments, W is selected from the group consisting of a bond, —C(O)—, and —S(O)₂—.

In some embodiments, X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted by arylene, heteroarylene or heterocyclylene or by one or more —O— groups. In some embodiments, X is C_1-4alkylene.

In some embodiments, Y is selected from the group consisting of —S(O)_0-2—, —S(O)₂—N(R₈)—, —C(R₆)—, —C(R₆)—O—, —O—C(R₆)—, —O—C(O)—O—, —N(R₈)-Q-, —C(R₆)—N(R₈)—,

embedded image

In some embodiments, Y is selected from the group consisting of —S(O)_0-2—, —C(O)—, —C(O)—O—, —N(R₈)-Q-, —C(R₆)—N(R₈)—, and —C(R₆)—N(OR₉)—. In some embodiments, Y is —S(O)_0-2—, —S(O)₂—N(R₈)—, —C(O)—, —N(R₈)—C(O)—, —N(R₈)—S(O)₂—, and —N(R₈)—C(R₆)—N(R₈)—. In some embodiments, Y is selected from the group consisting of —S(O)_0-2—, —C(O)—, —N(R₈)—C(O)—, —N(R₈)—S(O)₂—, and —N(R₈)—C(R₆)—N(R₈)—. In some embodiments, Y is —S(O)₂—, —C(O)—N(R₈)—, or —N(R₈)-Q-. In some embodiments, Y is —N(R₈)—C(R₆)—. In some embodiments, Y is —N(R₈)—S(O)₂—. In some embodiments, Y is —N(R₈)—C(R₆)—N(R₈)—.

In some embodiments, Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene wherein alkylene, alkenylene, and alkynylene are optionally interrupted with —O—. In some embodiments, Z is a bond, alkylene, or alkylene interrupted with one —O—. In some embodiments, Z is —C_1-3alkylene-. In some embodiments, Z is —CH₂—.

In some embodiments, a and b are independently integers from 1 to 6 with the proviso that a+b is ≦7.

In some embodiments, n is 0 or 1. In some embodiments, n is 0.

For certain embodiments of the compounds of Formulas (I) through (VI), the —NH₂group can be replaced by an —NH-G group, as shown in the compound of Formula (VII), to form prodrugs. In such embodiments, G is selected from the group consisting of: —C(O)—R′, α-aminoacyl, α-aminoacyl-α-aminoacyl, —C(O)—O—R′, —C(O)—N(R″)R′, —C(═NY′)—R′, —CH(OH)—C(O)—OY′, —CH(OC_1-4alkyl)Y₀, —CH₂Y₁, and —CH(CH₃)Y₁. In some of these embodiments G is —C(O)—R′, α-aminoacyl, α-aminoacyl-α-aminoacyl, or —C(O)—O—R′. Preferably, R′ and R″ are independently selected from the group consisting of C_1-10alkyl, C_3-7cycloalkyl, and benzyl, each of which may be unsubstituted or substituted by one or more substitutents selected from the group consisting of halogen, hydroxy, nitro, cyano, carboxy, C_1-6alkyl, C_1-4alkoxy, aryl, heteroaryl, arylC_1-4alkylenyl, heteroarylC_1-4alkylenyl, haloC_1-4alkylenyl, haloC_1-4alkoxy, —O—C(O)—CH₃, —C(O)—O—CH₃, —C(O)—NH₂, —O—CH₂—C(O)—NH₂, —NH₂, and —S(O)₂—NH₂. R″ can also be hydrogen. Preferably, α-aminoacyl is an acyl group derived from an amino acid selected from the group consisting of racemic, D-, and L-amino acids. Preferably, Y′ is selected from the group consisting of hydrogen, C_1-6alkyl, and benzyl. Preferably, Y₀is selected from the group consisting of C_1-6alkyl, carboxyC_1-6alkylenyl, aminoC_1-4alkylenyl, mono-N—C_1-6alkylaminoC_1-4alkylenyl, and di-N,N—C_1-6alkylaminoC_1-4alkylenyl. Preferably, Y₁is selected from the group consisting of mono-N—C_1-6alkylamino, di-N,N—C_1-6alkylamino, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, and 4-C_1-4alkylpiperazin-1-yl.

In some embodiments, R₃is —O—Z—Ar′—Y—R₄, —O—Z—Ar—X—Y—R₄, or —O—Z—Ar′—R₅. In some embodiments, R₃is —O—Z—Ar′—Y—R₄. In such embodiments of R₃, Ar′ is phenylene, naphthylene, pyridylene, pyrrolylene, thienylene, or furylene; Y is selected from the group consisting of —S(O)_0-2—, —C(O)—, —C(O)—O—, —N(R₈)-Q-, —C(R₆)—N(R₈)—, and —C(R₆)—N(OR₉)—; X is C_1-4alkylene; R₄is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and heterocyclyl; and R₅is

embedded image

In such embodiments, preferably, Q is selected from the group consisting of a bond, —C(O)—, —S(O)₂—, and —C(R₆)—N(R₈)—; and R₈is selected from the group consisting of hydrogen, C_1-4alkyl, and alkoxyalkylenyl.

Alternatively, in such embodiments of R₃, particularly when R₃is preferably Ar′ is phenylene, naphthylene, pyridylene, pyrrolylene, thienylene, or furylene (more preferably, phenylene); Y is selected from the group consisting of —S(O)_0-2—, —S(O)₂—N(R₈)—, —C(O)—, —N(R₈)—C(O)—, —N(R₈)—S(O)₂—, and —N(R₈)—C(R₆)—N(R₈)—; and R₄is selected from the group consisting of alkyl, aryl, heteroaryl, heteroarylalkylenyl, and heterocyclyl. In such embodiments, preferably, R₈is selected from the group consisting of hydrogen, C_1-4alkyl, and alkoxyalkylenyl.

In some embodiments of R₃, Y is —N(R₈)—C(R₆)—; R₄is alkyl, aryl, heteroaryl, or heterocyclyl; and R₈is hydrogen, C_1-4alkyl, or alkoxyalkylenyl. In some embodiments of R₃, Y is —N(R₈)—S(O)₂—; R₄is alkyl, aryl, heteroaryl, or heterocyclyl; and R₈is hydrogen, C_1-4alkyl, or alkoxyalkylenyl. In some embodiments of R₃, Y is —N(R₈)—C(R₆)—N(R₈)—; R₄is alkyl, aryl, heteroaryl, or heterocyclyl; and R₈is hydrogen, C_1-4alkyl, or alkoxyalkylenyl.

In some embodiments of R₃, Y is —S(O)₂—, —C(O)—N(R₈)—, or —N(R₈)-Q-; R₈is selected from the group consisting of hydrogen, C_1-4alkyl, and alkoxyalkylenyl; and R₄is selected from the group consisting of hydrogen, alkyl, aryl, arylalkylenyl, heteroaryl, and heteroarylalkylenyl.

In one aspect, the present invention provides thiazoloquinoline and thiazolonaphthyridine compounds of the following formula (I):

embedded image

wherein:

R_Aand R_Btaken together form a fused benzene ring or fused pyridine ring wherein the benzene ring or pyridine ring is substituted by one R₃group, or substituted by one R₃group and one R group;

R₂is selected from the group consisting of:

- hydrogen,
- alkyl,
- hydroxyalkylenyl,
- haloalkylenyl,
- alkenyl,
- alkyl-O-alkylenyl,
- alkyl-O-alkenylenyl,
- alkenyl-O-alkylenyl,
- alkenyl-O-alkenylenyl,
- N(R₈)₂-alkylenyl,
- N₃-alkylenyl,
- N(R₈)₂—C(O)—O-alkylenyl,
- heterocyclyl,
- heterocyclyl-O-alkylenyl,
- heterocyclyl-O-alkenylenyl,
- aryl,
- aryl-O-alkylenyl,
- aryl-O-alkenylenyl,
- heteroaryl,
- heteroaryl-O-alkylenyl, and
- heteroaryl-O-alkenylenyl;

R₃is selected from the group consisting of:

- —O—Z—Ar,
- —O—Z—Ar′-Y—R₄,
- —O—Z—Ar′—R₅, and
- —O—Z—Ar′—X—R₅;

Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene wherein alkylene, alkenylene, and alkynylene are optionally interrupted with —O—;

Ar is selected from the group consisting of aryl and heteroaryl both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, heterocyclylalkylene, amino, alkylamino, and dialkylamino;

Ar′ is selected from the group consisting of arylene and heteroarylene both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, and dialkylamino;

X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted by arylene, heteroarylene or heterocyclylene or by one or more —O— groups.

Y is selected from the group consisting of:

- —S(O)_0-2—,
- —S(O)₂—N(R₈)—,
- —C(R₆)—,
- —C(R₆)—O—,
- —O—C(R₆)—,
- —O—C(O)—O—,
- —N(R₈)-Q-,
- —C(R₆)—N(R₈)—,
- —O—C(R₆)—N(R₈)—,
- —C(R₆)—N(OR₉)—,

embedded image

R₄is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R₅is selected from the group consisting of:

embedded image

R₆is selected from the group consisting of ═O and ═S;

R₇is C_2-7alkylene;

R₈is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R₉is selected from the group consisting of hydrogen and alkyl;

R₁₀is C_3-8alkylene;

A is selected from the group consisting of —O—, —C(O)—, —S(O)_0-2—, —CH₂—, and —N(R₄)—;

Q is selected from the group consisting of a bond, —C(R₆)—, —C(R₆)—C(R₆)—, —S(O)₂—, —C(R₆)—N(R₈)—W—, —S(O)₂—N(R₈)—, —C(R₆)—O—, and —C(R₆)—N(OR₉)—;

V is selected from the group consisting of —C(R₆)—, —O—C(R₆)—, —N(R₈)—C(R₆)—, and —S(O)₂—;

W is selected from the group consisting of a bond, —C(O)—, and —S(O)₂—;

a and b are independently integers from 1 to 6 with the proviso that a+b is ≦7; and

R is selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

In some embodiments, compounds or salts of Formula I induce the biosynthesis of one or more cytokines.

In some embodiments of Formula I, Z is a bond, alkylene, or alkylene interrupted with one —O—. In certain embodiments, Z is —C_1-3alkylene-.

In some embodiments of Formula I, R₃is —O—Z—Ar. In certain embodiments, Z is a bond, alkylene, or alkylene interrupted with one —O—. In certain embodiments, Z is —C_1-3alkylene-.

In some embodiments of Formula I, R₃is —O—Z—Ar′-Y—R₄, —O—Z—Ar′—X—Y—R₄, or —O—Z—Ar—R₅. In certain embodiments, Z is a bond, alkylene, or alkylene interrupted with one —O—. In certain embodiments, Z is —C_1-3alkylene-.

In some embodiments of Formula I, R₃is —O—Z—Ar′—Y—R₄. In certain embodiments, Z is a bond, alkylene, or alkylene interrupted with one —O—. In certain embodiments, Z is —C_1-3alkylene-. In certain embodiments, Y is —S(O)₂—, —C(O)—N(R₈)—, or —N(R₈)-Q-; R₈is selected from the group consisting of hydrogen, C_1-4alkyl, and alkoxyalkylenyl; and R₄is selected from the group consisting of hydrogen, alkyl, aryl, arylalkylenyl, heteroaryl, and heteroarylalkylenyl.

For some embodiments of Formula I or any one of the above embodiments, R₂is selected from the group consisting of hydrogen, C_1-8alkyl, and C_1-8alkyl-O—C_1-8alkylenyl.

The present invention also provides thiazoloquinoline compounds of the following formula (II):

embedded image

wherein:

R₂is selected from the group consisting of:

- hydrogen,
- alkyl,
- hydroxyalkylenyl,
- haloalkylenyl,
- alkenyl,
- alkyl-O-alkylenyl,
- alkyl-O-alkenylenyl,
- alkenyl-O-alkylenyl,
- alkenyl-O-alkenylenyl,
- N(R₈)₂-alkylenyl,
- N₃-alkylenyl,
- N(R₈)₂—C(O)—O-alkylenyl,
- heterocyclyl,
- heterocyclyl-O-alkylenyl,
- heterocyclyl-O-alkenylenyl,
- aryl,
- aryl-O-alkylenyl,
- aryl-O-alkenylenyl,
- heteroaryl,
- heteroaryl-O-alkylenyl, and
- heteroaryl-O-alkenylenyl;

R₃is selected from the group consisting of:

- —O—Z—Ar,
- —O—Z—Ar′—Y—R₄,
- —O—Z—Ar′—X—Y—R₄,
- —O—Z—Ar′—R₅, and
- —O—Z—Ar′—X—R₅;

Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene wherein alkylene, alkenylene, and alkynylene are optionally interrupted with —O—;

Y is selected from the group consisting of:

- —S(O)_0-2—,
- —S(O)₂—N(R₈)—,
- —C(R₆)—,
- —C(R₆)—O—,
- —O—C(R₆)—,
- —O—C(O)—O—,
- —N(R₈)-Q-,
- —C(R₆)—N(R₈)—,
- —O—C(R₆)—N(R₈)—,
- —C(R₆)—N(OR₉)—,

embedded image

R₅is selected from the group consisting of:

embedded image

R₆is selected from the group consisting of ═O and ═S;

R₇is C_2-7alkylene;

R₈is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R₉is selected from the group consisting of hydrogen and alkyl;

R₁₀is C_3-8alkylene;

A is selected from the group consisting of —O—, —C(O)—, —S(O)_0-2—, —CH₂—, and —N(R₄)—;

V is selected from the group consisting of —C(R₆)—, —O—C(R₆)—, —N(R₈)—C(R₆)—, and —S(O)₂—;

W is selected from the group consisting of a bond, —C(O)—, and —S(O)₂—;

a and b are independently integers from 1 to 6 with the proviso that a+b is ≦7;

R is selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, and trifluoromethyl; and

n is 0 or 1;

or a pharmaceutically acceptable salt thereof.

In some embodiments of Formula II, Z is a bond, alkylene, or alkylene interrupted with one —O—. In certain embodiments, Z is —C_1-3alkylene-. In certain embodiments, Z is —CH₂—.

In some embodiments of Formula II, R₃is —O—Z—Ar. In certain embodiments, Ar is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrrolyl, thienyl, furyl, isoxazolyl, thiazolyl, imidazolyl, benzimidazolyl, indolyl, benzothiazolyl, and oxazolyl; each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, trifluoromethoxy, aryl, and hydroxyalkyl. In certain embodiments, Ar is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrrolyl, thienyl, furyl, isoxazolyl, thiazolyl, and imidazolyl; each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, trifluoromethyl, or trifluoromethoxy. In certain embodiments, Ar is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrrolyl, thienyl, furyl, isoxazolyl, thiazolyl, and imidazolyl; each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, and trifluoromethoxy.

In certain embodiments, Ar is phenyl substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, trifluoromethyl, or trifluoromethoxy. In certain embodiments, phenyl substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, and trifluoromethoxy. In certain embodiments, Z is —C_1-3alkylene-. In certain embodiments, Z is —CH₂—.

In some embodiments of Formula II, R₃is —O—Z—Ar′-Y—R₄, —O—Z—Ar—X—Y—R₄, or —O—Z—Ar′—R₅. In certain embodiments, Ar′ is phenylene, naphthylene, pyridylene, pyrrolylene, thienylene, or furylene; Y is selected from the group consisting of —S(O)_0-2—, —C(O)—, —C(O)—O—, —N(R₈)-Q-, —C(R₆)—N(R₈)—, and —C(R₆)—N(OR₉)—;

wherein Q is selected from the group consisting of a bond, —C(O)—, —S(O)₂—, and —C(R₆)—N(R₈)—; and R₈is selected from the group consisting of hydrogen, C_1-4alkyl, and alkoxyalkylenyl; X is C_1-4alkylene; R₄is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and heterocyclyl; and R₅is

embedded image

In certain embodiments, Z is —C_1-3alkylene-. In certain embodiments, Z is —CH₂—. In certain embodiments, R₃is —O—Z—Ar′—Y—R₄.

In some embodiments of Formula II, R₃is —O—Z—Ar′—Y—R₄. In certain embodiments, Ar′ is phenylene, naphthylene, pyridylene, pyrrolylene, thienylene, or furylene; Y is selected from the group consisting of —S(O)_0-2—, —C(O)—, —N(R₈)—C(O)—, —N(R₈)—S(O)₂—, and —N(R₈)—C(R₆)—N(R₈)—, wherein R₈is selected from the group consisting of hydrogen, C_1-4alkyl, and alkoxyalkylenyl; and R₄is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl. In certain embodiments, Y is —N(R₈)—C(R₆)—; R₄is alkyl, aryl, heteroaryl, or heterocyclyl; and R₈is hydrogen, C_1-4alkyl, or alkoxyalkylenyl. In certain other embodiments, Y is —N(R₈)—S(O)₂—; R₄is alkyl, aryl, heteroaryl, or heterocyclyl; and R₈is hydrogen, C_1-4alkyl, or alkoxyalkylenyl. In certain other embodiments, Y is —N(R₈)—C(R₆)—N(R₈)—; R₄is alkyl, aryl, heteroaryl, or heterocyclyl; and R₈is hydrogen, C_1-4alkyl, or alkoxyalkylenyl.

In some embodiments of Formula II and any one of the above embodiments of Formula II, R₂is selected from the group consisting of hydrogen, C_1-8alkyl, and C_1-8alkyl-O—C_1-8alkylenyl. In certain embodiments, R₂is hydrogen, C_1-4alkyl or C_1-4alkyl-O—C_1-4alkylenyl. In certain more specific embodiments, R₂is methyl, ethyl, n-propyl, n-butyl, 2-methoxyethyl, methoxymethyl, or ethoxymethyl.

In some embodiments of Formula II and any one of the above embodiments of Formula II, R₃is attached at the 7-position.

In some embodiments of Formula II and any one of the above embodiments of Formula II, n is 0.

The present invention also provides thiazolonaphthyridine compounds of the following formulas (III, IV, V, and VI):

embedded image

wherein:

R₂is selected from the group consisting of:

- hydrogen,
- alkyl,
- hydroxyalkylenyl,
- haloalkylenyl,
- alkenyl,
- alkyl-O-alkylenyl,
- alkyl-O-alkenylenyl,
- alkenyl-O-alkylenyl,
- alkenyl-O-alkenylenyl,
- N(R₈)₂-alkylenyl,
- N₃-alkylenyl,
- N(R₈)₂—C(O)—O-alkylenyl,
- heterocyclyl,
- heterocyclyl-O-alkylenyl,
- heterocyclyl-O-alkenylenyl,
- aryl,
- aryl-O-alkylenyl,
- aryl-O-alkenylenyl,
- heteroaryl,
- heteroaryl-O-alkylenyl, and
- heteroaryl-O-alkenylenyl;

R₃is selected from the group consisting of:

- —O—Z—Ar,
- —O—Z—Ar′—Y—R₄,
- —O—Z—Ar′—X—Y—R₄,
- —O—Z—Ar′—R₅, and
- —O—Z—Ar′—X—R₅;

Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene wherein alkylene, alkenylene, and alkynylene are optionally interrupted with —O—;

Y is selected from the group consisting of:

- —S(O)_0-2—,
- —S(O)₂—N(R₈)—,
- —C(R₆)—,
- —C(R₆)—O—,
- —O—C(R₆)—,
- —O—C(O)—O—,
- —N(R₈)-Q-,
- —C(R₆)—N(R₈)—,
- —O—C(R₆)—N(R₈)—,
- —C(R₆)—N(OR₉)—,

embedded image

R₅is selected from the group consisting of:

embedded image

R₆is selected from the group consisting of ═O and ═S;

R₇is C_2-7alkylene;

R₈is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R₉is selected from the group consisting of hydrogen and alkyl;

R₁₀is C_3-8alkylene;

A is selected from the group consisting of —O—, —C(O)—, —S(O)_0-2—, —CH₂—, and —N(R₄)—;

V is selected from the group consisting of —C(R₆)—, —O—C(R₆)—, —N(R₈)—C(R₆)—, and —S(O)₂—;

W is selected from the group consisting of a bond, —C(O)—, and —S(O)₂—;

a and b are independently integers from 1 to 6 with the proviso that a+b is ≦7;

R is selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, and trifluoromethyl; and

n is 0 or 1;

or a pharmaceutically acceptable salt thereof.

In some embodiments of Formulas III, IV, V, and VI, Z is a bond, alkylene, or alkylene interrupted with one —O—. In certain embodiments, Z is —C_1-3alkylene-. In certain embodiments, Z is —CH₂—.

In some embodiments of Formulas III, IV, V, and VI, R₃is —O—Z—Ar. In certain embodiments, Ar is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrrolyl, thienyl, furyl, isoxazolyl, thiazolyl, and imidazolyl; each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, trifluoromethyl, or trifluoromethoxy. In certain embodiments, Ar is phenyl substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, nitro, cyano, halogen, amino, alkylamino, dialkylamino, trifluoromethyl, or trifluoromethoxy. In certain embodiments, Z is —C_1-3alkylene-. In certain embodiments, Z is —CH₂—.

In some embodiments of Formulas III, IV, V, and VI, R₃is —O—Z—Ar′—Y—R₄, —O—Z—Ar—X—Y—R₄, or —O—Z—Ar′—R₅. In certain embodiments, Ar′ is phenylene, naphthylene, pyridylene, pyrrolylene, thienylene, or furylene; Y is selected from the group consisting of —S(O)_0-2—, —C(O)—, —C(O)—O—, —N(R₈)-Q-, —C(R₆)—N(R₉)—, and —C(R₆)—N(OR₉)—;

embedded image

In certain embodiments, Z is —C_1-3alkylene-. In certain embodiments, Z is —CH₂—. In certain embodiments, R₃is —O—Z—Ar′—Y—R₄.

In some embodiments of Formulas III, IV, V, and VI, R₃is —O—Z—Ar′—Y—R₄. In certain embodiments, Y is —N(R₈)—C(R₆)—; R₄is alkyl, aryl, heteroaryl, or heterocyclyl; and R₈is hydrogen, C_1-4alkyl, or alkoxyalkylenyl. In certain other embodiments, Y is —N(R₈)—S(O)₂—; R₄is alkyl, aryl, heteroaryl, or heterocyclyl; and R₈is hydrogen, C_1-4alkyl, or alkoxyalkylenyl. In certain other embodiments, Y is —N(R₈)—C(R₆)—N(R₈)—; R₄is alkyl, aryl, heteroaryl, or heterocyclyl; and R₈is hydrogen, C_1-4alkyl, or alkoxyalkylenyl.

In some embodiments of Formulas III, IV, V, and VI and any one of the above embodiments of Formulas III, IV, V, and VI, R₂is selected from the group consisting of hydrogen, C_1-8alkyl, and C_1-8alkyl-O—C_1-8alkylenyl. In certain embodiments, R₂is hydrogen, C_1-4alkyl or C_1-4alkyl-O—C_1-4alkylenyl. In certain more specific embodiments, R₂is methyl, ethyl, n-propyl, n-butyl, 2-methoxyethyl, methoxymethyl, or ethoxymethyl.

In some embodiments of Formulas III, IV, and VI and any one of the above embodiments described above for Formulas III, IV, and VI, R₃is attached at the 7-position. That is, the thiazolonaphthyridines selected from Formulas III, IV, V, and VI are the compounds of the formulas (IIIa, IVa, and VIa):

embedded image

In some embodiments, the thiazolonaphthyridines selected from Formulas III, IV, V, and VI or any one of the above embodiments described above for Formulas III, IV, V, and VI are the compounds of the formula (III):

embedded image

In some embodiments of Formulas III, IV, V, and VI or any one of the above embodiments of Formulas III, IV, V, and VI, n is 0.

In another aspect of the invention, there is provided a compound (which is a prodrug) of the formula (VII):

embedded image

wherein:

R_Aand R_Btaken together form a fused benzene ring or fused pyridine ring wherein the benzene ring or pyridine ring is substituted by one R₃group, or substituted by one R₃group and one R group;

R₂is selected from the group consisting of:

- hydrogen,
- alkyl,
- hydroxyalkylenyl,
- haloalkylenyl,
- alkenyl,
- alkyl-O-alkylenyl,
- alkyl-O-alkenylenyl,
- alkenyl-O-alkylenyl,
- alkenyl-O-alkenylenyl,
- N(R₈)₂-alkylenyl,
- N₃-alkylenyl,
- N(R₈)₂—C(O)—O-alkylenyl,
- heterocyclyl,
- heterocyclyl-O-alkylenyl,
- heterocyclyl-O-alkenylenyl,
- aryl,
- aryl-O-alkylenyl,
- aryl-O-alkenylenyl,
- heteroaryl,
- heteroaryl-O-alkylenyl, and
- heteroaryl-O-alkenylenyl;

R₃is selected from the group consisting of:

- —O—Z—Ar,
- —O—Z—Ar′—Y—R₄,
- —O—Z—Ar′—X—Y—R₄,
- —O—Z—Ar′—R₅, and
- —O—Z—Ar′—X—R₅;

Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene wherein alkylene, alkenylene, and alkynylene are optionally interrupted with —O—;

Y is selected from the group consisting of:

- —S(O)_0-2—,
- —S(O)₂—N(R₈)—,
- —C(R₆)—,
- —C(R₆)—O—,
- —O—C(R₆)—,
- —O—C(O)—O—,
- —N(R₈)-Q-,
- —C(R₆)—N(R₈)—,
- —O—C(R₆)—N(R₈)—,
- —C(R₆)—N(OR₉)—,

embedded image

R₅is selected from the group consisting of:

embedded image

R₆is selected from the group consisting of ═O and ═S;

R₇is C_2-7alkylene;

R₈is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R₉is selected from the group consisting of hydrogen and alkyl;

R₁₀is C_3-8alkylene;

A is selected from the group consisting of —O—, —C(O)—, —S(O)_0-2—, —CH₂—, and —N(R₄)—;

V is selected from the group consisting of —C(R₆)—, —O—C(R₆)—, —N(R₈)—C(R₆)—, and —S(O)₂—;

W is selected from the group consisting of a bond, —C(O)—, and —S(O)₂—;

a and b are independently integers from 1 to 6 with the proviso that a+b is ≦7;

R is selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, and trifluoromethyl;

G is selected from the group consisting of:

- —C(O)—R′,
- α-aminoacyl,
- α-aminoacyl-α-aminoacyl,
- —C(O)—O—R′,
- —C(O)—N(R″)R′,
- —CH(OH)—C(O)—OY′,
- —CH(OC_1-4alkyl)Y₀,
- —CH₂Y₁, and
- —CH(CH₃)Y₁;

R′ and R″ are independently selected from the group consisting of C_1-10alkyl, C_3-7cycloalkyl, and benzyl, each of which may be unsubstituted or substituted by one or more substitutents selected from the group consisting of halogen, hydroxy, nitro, cyano, carboxy, C_1-6alkyl, C_1-4alkoxy, aryl, heteroaryl, arylC_1-4alkylenyl, heteroarylC_1-4alkylenyl, haloC_1-4alkylenyl, haloC_1-4alkoxy, —O—C(O)—CH₃, —C(O)—O—CH₃, —C(O)—NH₂, —O—CH₂—C(O)—NH₂, —NH₂, and —S(O)₂—NH₂, with the proviso that R″ can also be hydrogen;

α-aminoacyl is an acyl group derived from an amino acid selected from the group consisting of racemic, D-, and L-amino acids;

Y′ is selected from the group consisting of hydrogen, C_1-6alkyl, and benzyl;

Y₀is selected from the group consisting of C_1-6alkyl, carboxyC_1-6alkylenyl, aminoC_1-4alkylenyl, mono-N—C_1-6alkylaminoC_1-4alkylenyl, and di-N,N—C_1-6alkylaminoC_1-4alkylenyl;

Y₁is selected from the group consisting of mono-N—C_1-6alkylamino, di-N,N—C_1-6alkylamino, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, and 4-C_1-4alkylpiperazin-1-yl;

or a pharmaceutically acceptable salt thereof.

As used herein, the terms “alkyl,” “alkenyl,” “alkynyl” and the prefix “alk-” are inclusive of both straight chain and branched chain groups and of cyclic groups, e.g., cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms, and alkynyl groups containing from 2 to 20 carbon atoms. In some embodiments, these groups have a total of up to 10 carbon atoms, up to 8 carbon atoms, up to 6 carbon atoms, or up to 4 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl, adamantyl, and substituted and unsubstituted bornyl, norbornyl, and norbornenyl.

Unless otherwise specified, “alkylene,” “alkenylene,” and “alkynylene” are the divalent forms of the “alkyl,” “alkenyl,” and “alkynyl” groups defined above. The terms “alkylenyl,” “alkenylenyl,” and “alkynylenyl” are used when “alkylene”, “alkenylene:, and “alkynylene”, respectively, are substituted. For example, an arylalkylenyl group comprises an “alkylene” moiety to which an aryl group is attached.

The term “haloalkyl” is inclusive of alkyl groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of other groups that include the prefix “halo-”. Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.

The term “aryl” as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl.

The term “heteroatom” refers to the atoms O, S, or N.

The term “heteroaryl” includes aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N). In some embodiments, the term “heteroaryl” includes a ring or ring system that contains 2 to 12 carbon atoms, 1 to 3 rings, 1 to 4 heteroatoms, and O, S, and/or N as the heteroatoms. Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, pyrazinyl, 1-oxidopyridyl, pyridazinyl, triazinyl, tetrazinyl, oxadiazolyl, thiadiazolyl, and so on.

The term “heterocyclyl” includes non-aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups. In some embodiments, the term “heterocyclyl” includes a ring or ring system that contains 2 to 12 carbon atoms, 1 to 3 rings, 1 to 4 heteroatoms, and O, S, and N as the heteroatoms. Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, tetrahydropyranyl, quinuclidinyl, homopiperidinyl (azepanyl), homopiperazinyl (diazepanyl), 1,4-oxazepanyl, 1,3-dioxolanyl, aziridinyl, azetidinyl, dihydroisoquinolin-(1H)-yl, octahydroisoquinolin-(1H)-yl, dihydroquinolin-(2H)-yl, octahydroquinolin-(2H)-yl, dihydro-1H-imidazolyl, 3-azabicyclo[3.2.2]non-3-yl, and the like.

The term “heterocyclyl” includes bicyclic and tricyclic heterocyclic ring systems. Such ring systems include fused and/or bridged rings and spiro rings. Fused rings can include, in addition to a saturated or partially saturated ring, an aromatic ring, for example, a benzene ring. Spiro rings include two rings joined by one spiro atom and three rings joined by two spiro atoms.

When “heterocyclyl” contains a nitrogen atom, the point of attachment of the heterocyclyl group may be the nitrogen atom.

The terms “arylene,” “heteroarylene,” and “heterocyclylene” are the divalent forms of the “aryl,” “heteroaryl,” and “heterocyclyl” groups defined above. Likewise, “arylenyl,” “heteroarylenyl,” and “heterocyclylenyl” are the divalent forms of the “aryl,” “heteroaryl,” and “heterocyclyl” groups defined above. For example, an alkylarylenyl group comprises an arylene moiety to which an alkyl group is attached.

When a group (or substituent or variable) is present more that once in any Formula described herein, each group (or substituent or variable) is independently selected, whether specifically stated or not. For example, for the formula N(R₈)₂-alkylenyl, each R₈group is independently selected.

The invention is inclusive of the compounds described herein and salts thereof in any of their pharmaceutically acceptable forms, including isomers such as diastereomers and enantiomers, solvates, polymorphs, prodrugs, and the like. In particular, if a compound is optically active, the invention specifically includes each of the compound's enantiomers as well as racemic mixtures of the enantiomers. It should be understood that the term “compound” includes any or all of such forms, whether explicitly stated or not (although at times, “salts” are explicitly stated).

The term “prodrug” means a compound that can be transformed in vivo to yield an immune response modifying compound in any of the salt, solvated, polymorphic, or isomeric forms described above. The prodrug, itself, may be an immune response modifying compound in any of the salt, solvated, polymorphic, or isomeric forms described above. The transformation may occur by various mechanisms, such as through a chemical (e.g., solvolysis or hydrolysis, for example, in the blood) or enzymatic biotransformation. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A. C. S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

Preparation of the Compounds

Compounds of the invention may be synthesized by synthetic routes that include processes analogous to those well known in the chemical arts, particularly in light of the description contained herein. The starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wis., USA) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19, Wiley, New York, (1967-1999 ed.); Alan R. Katritsky, Otto Meth-Cohn, Charles W. Rees, Comprehensive Organic Functional Group Transformations, v 1-6, Pergamon Press, Oxford, England, (1995); Barry M. Trost and Ian Fleming, Comprehensive Organic Synthesis, v. 1-8, Pergamon Press, Oxford, England, (1991); or Beilsteins Handbuch der organischen Chemie, 4, Aufl. Ed. Springer-Verlag, Berlin, Germany, including supplements (also available via the Beilstein online database)).

For illustrative purposes, the reaction schemes depicted below provide potential routes for synthesizing the compounds of the present invention as well as key intermediates. For more detailed description of the individual reaction steps, see the EXAMPLES section below. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the compounds of the invention. Although specific starting materials and reagents are depicted in the reaction schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional methods well known to those skilled in the art.

Conventional methods and techniques of separation and purification can be used to isolate compounds of the invention, as well as various intermediates related thereto. Such techniques may include, for example, all types of chromatography (high performance liquid chromatography (HPLC), column chromatography using common absorbents such as silica gel, and thin layer chromatography), recrystallization, and differential (i.e., liquid-liquid) extraction techniques.

Compounds of the invention can be prepared according to Reaction Scheme I where R, R₂, and n are as defined above and R_3ais —Z—Ar or —Z—Ar′—Y—R₄, where Z, Ar, Ar′, Y, and R₄are as defined above. In step (1) of Reaction Scheme I, a benzyloxyaniline of Formula XV is treated with the condensation product generated from 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) and triethyl orthoformate to provide a dione of Formula XVI. The reaction is conveniently carried out by adding a solution of a benzyloxyaniline of Formula XV to a heated mixture of Meldrum's acid and triethyl orthoformate and heating the reaction at an elevated temperature such as 45° C.

In step (2) of Reaction Scheme I, a dione of Formula XVI undergoes thermolysis and cyclization to provide a benzyloxyquinolin-4-ol of Formula XVII. The reaction is conveniently carried out in a heat transfer fluid such as DOWTHERM A at a temperature between 200 and 250° C.

In step (3) of Reaction Scheme I, the benzyloxyquinolin-4-ol of Formula XVII is nitrated under conventional nitration conditions to provide a benzyloxy-3-nitroquinolin-4-ol of Formula XVIII. The reaction is conveniently carried out by adding nitric acid to the benzyloxyquinolin-4-ol of Formula XVII in a suitable solvent such as propionic acid and heating the mixture at an elevated temperature such as 125° C.

In step (4) of Reaction Scheme I, a benzyloxy-3-nitroquinolin-4-ol of Formula XVIII is reduced to provide a 3-amino-benzyloxyquinolin-4-ol of Formula XIX. The reaction can be carried out by hydrogenation using a heterogeneous hydrogenation catalyst such as platinum on carbon. The hydrogenation is conveniently carried out in a Parr apparatus in a suitable solvent such as N,N-dimethylformamide. The reaction can be carried out at ambient temperature.

In step (5) of Reaction Scheme I, a 3-amino-benzyloxyquinolin-4-ol of Formula XIX is reacted with a carboxylic acid or an equivalent thereof to provide a compound of Formula XX. Suitable equivalents to carboxylic acid include acid anhydrides and acid chlorides. The reaction is conveniently carried out by adding the acid chloride to a solution of a 3-amino-benzyloxyquinolin-4-ol of Formula XIX in a suitable solvent such as dichloromethane or acetonitrile in the presence of a tertiary amine such as triethylamine, pyridine, or 4-dimethylaminopyridine to afford an amide. The reaction can be carried out at or below ambient temperature.

In step (6) of Reaction Scheme I, an amide of Formula XX is reacted with phosphorus pentasulfide to provide a benzyloxy-thiazolo[4,5-c]quinoline of Formula XXI. The reaction can be carried out by adding phosphorus pentasulfide to a solution or suspension of a compound of Formula XX in a suitable solvent such as pyridine and heating the resulting mixture.

In step (7) of Reaction Scheme I, a benzyloxy-thiazolo[4,5-c]quinoline of Formula XXI is oxidized to provide a benzyloxy-thiazolo[4,5-c]quinoline-5N-oxide of Formula XXII using a conventional oxidizing agent capable of forming N-oxides. The reaction is conveniently carried out by adding 3-chloroperoxybenzoic acid to a solution of a compound of Formula XXI in a solvent such dichloromethane or chloroform. The reaction can be carried out at ambient temperature.

In step (8) of Reaction Scheme I, a benzyloxy-thiazolo[4,5-c]quinoline-5N-oxide of Formula XXII is aminated to provide a benzyloxy-thiazolo[4,5-c]quinolin-4-amine of Formula XXIII. Step (8) can be carried out by the activation of an N-oxide of Formula XXII by conversion to an ester and then reacting the ester with an aminating agent. Suitable activating agents include alkyl- or arylsulfonyl chlorides such as benzenesulfonyl chloride, methanesulfonyl chloride, or p-toluenesulfonyl chloride. Suitable aminating agents include ammonia, in the form of ammonium hydroxide, for example, and ammonium salts such as ammonium carbonate, ammonium bicarbonate, and ammonium phosphate. The reaction is conveniently carried out by adding ammonium hydroxide followed by p-toluenesulfonyl chloride to a solution of the N-oxide of Formula XXII in a suitable solvent such as 1,2-dichloroethane at elevated temperature. The reaction may be carried out by adding ammonium hydroxide and p-toluenesulfonyl chloride to the reaction mixture from step (7) without isolating the N-oxide of Formula XXII

Alternatively step (8) can be carried out by the reaction of a benzyloxy-thiazolo[4,5-c]quinoline-5N-oxide of Formula XXII with trichloroacetyl isocyanate followed by hydrolysis of the resulting intermediate to provide a benzyloxy-thiazolo[4,5-c]quinoline-4-amine of Formula XXIII. The reaction is conveniently carried out in two steps by (i) adding trichloroacetyl isocyanate to a solution of the N-oxide of Formula XXII in a solvent such as dichloromethane and stirring at ambient temperature to provide an isolable amide intermediate. In step (ii), a solution of the intermediate in methanol is treated with a base such as sodium methoxide or ammonium hydroxide at ambient temperature.

In step (9) of Reaction Scheme I, the benzyl group of a benzyloxy-thiazolo[4,5-c]quinoline-4-amine of Formula XXIII is cleaved to provide a thiazolo[4,5-c]quinolinol of Formula XXIV. The cleavage is conveniently carried out with an acid such as hydrogen bromide in a suitable solvent such as acetic acid at elevated temperature.

Alternatively, the cleavage may be carried out on a Parr apparatus under hydrogenolysis conditions using a suitable heterogeneous catalyst such as palladium on carbon in a solvent such as ethanol.

In step (10) of Reaction Scheme I, a thiazolo[4,5-c]quinolinol of Formula XXIV is converted to an ether-substituted thiazolo[4,5-c]quinoline-4-amine of Formula XXV using a Williamson-type ether synthesis. The reaction is effected by treating a thiazolo[4,5-c]quinolinol of Formula XXIV with an alkyl or aryl halide of Formula Halide-Z—Ar or Halide-Z—Ar′—Y—R₄in the presence of a base. Numerous reagents of Formulae Halide-Z—Ar and Halide-Z—Ar′—Y—R₄are commercially available, including substituted benzyl bromides and chlorides, substituted or unsubstituted arylalkylenyl bromides and chlorides, and substituted fluorobenzenes. Other reagents of Formulae Halide-Z—Ar and Halide-Z—Ar′—Y—R₄can be prepared using conventional synthetic methods. The reaction is conveniently carried out by combining a reagent of Formula Halide-Z—Ar or Halide-Z—Ar′—Y—R₄with a thiazolo[4,5-c]quinolinol of Formula XXIV in a solvent such as N,N-dimethylformamide (DMF) in the presence of a suitable base such as cesium carbonate. Optionally, catalytic tetrabutylammonium bromide can be added. The reaction can be carried out at ambient temperature or at an elevated temperature, for example 65° C. or 85° C., depending on the reactivity of the reagent of Formula Halide-Z—Ar or Halide-Z—Ar′—Y—R₄. The product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Alternatively, step (10) may be carried out using the Ullmann ether synthesis, in which an alkali metal aryloxide of a thiazolo[4,5-c]quinolinol of Formula XXIV reacts with an aryl halide in the presence of copper salts, to provide compounds of Formula XXV, where R_3ais —Z—Ar or —Z—Ar′—Y—R₄, and Z is a bond.

embedded image

Compounds of the invention can also be prepared according to Reaction Scheme II, where R, R₂, and n are as defined above and R_3ais —Z—Ar or —Z—Ar′—Y—R₄, where Z, Ar, Ar′, Y, and R₄are as defined above. In step (1) of Reaction Scheme II, the benzyl group of a benzyloxy-thiazolo[4,5-c]quinoline of Formula XXI is cleaved to provide a thiazolo[4,5-c]quinolinol of Formula XXVI. The reaction can be carried out as described in step (9) of Reaction Scheme I.

In step (2) of Reaction Scheme II, a thiazolo[4,5-c]quinolinol of Formula XXVI is treated with an alkyl or aryl halide of Formula Halide-Z—Ar or Halide-Z—Ar′—Y—R₄to afford an ether-substituted thiazolo[4,5-c]quinoline of Formula XXVII. The reaction can be carried out as described in step (10) of Reaction Scheme I.

In steps 3 and 4 of Reaction Scheme II, an ether-substituted thiazolo[4,5-c]quinoline of Formula XXVII is oxidized to afford a thiazolo[4,5-c]quinoline-5N-oxide of Formula XXVIII, which is aminated to provide a thiazolo[4,5-c]quinolin-4-amine of Formula XXV. Steps (3) and (4) can be carried out as described in steps (7) and (8), respectively, of Reaction Scheme I. The product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Further synthetic elaboration of ether-substituted thiazolo[4,5-c]quinolin-4-amines of Formula XXV, prepared in Reaction Scheme I or II, is possible. For example, a nitro substituent on the aryl or heteroaryl group on a compound of Formula II, where R_3ais —Z—Ar, can be reduced to an amino group using conventional methods. The reduction can be carried out using the methods described in step (4) of Reaction Scheme I.

embedded image

Compounds of the invention can also be prepared according to Reaction Scheme III where R, R₂, and n are as defined above and R_3ais —Z—Ar or —Z—Ar′—Y—R₄, where Z, Ar, Ar′, Y, and R₄are as defined above. In step (1) of Reaction Scheme III, a benzyloxypyridine of Formula XXX is treated with the condensation product generated from 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) and triethyl orthoformate to provide a dione of Formula XXXI. The reaction is conveniently carried out by adding a solution of a benzyloxypyridine of Formula XXX to a heated mixture of Meldrum's acid and triethyl orthoformate and heating the reaction at an elevated temperature such as 45° C. Benzyloxypyrdines of Formula XXX can be prepared using conventional synthetic methods; see for example, Holladay et al., Biorg. Med. Chem. Lett., (8), 1998, 2797-2802.

In step (2) of Reaction Scheme III, a dione of Formula XXXI undergoes thermolysis and cyclization to provide a benzyloxy[1,5]naphthyridin-4-ol of Formula XXXII. The reaction is conveniently carried out in a heat transfer fluid such as DOWTHERM A at a temperature between 200 and 250° C.

In step (3) of Reaction Scheme III, the benzyloxy[1,5]naphthyridin-4-ol of Formula XXXII is nitrated under conventional nitration conditions to provide a benzyloxy-3-nitro[1,5]naphthyridin-4-ol of Formula XXXIII. The reaction is conveniently carried out by adding nitric acid to the benzyloxy[1,5]naphthyridin-4-ol of Formula XXXII in a suitable solvent such as propionic acid and heating the mixture at an elevated temperature such as 125° C.

In step (4) of Reaction Scheme III, a benzyloxy-3-nitro[1,5]naphthyridin-4-ol of Formula XXXIII is reduced to provide a 3-amino-benzyloxy[1,5]naphthyridin-4-ol of Formula XXXIV. The reaction can be carried out by hydrogenation using a heterogeneous hydrogenation catalyst such as platinum on carbon. The hydrogenation is conveniently carried out in a Parr apparatus in a suitable solvent such as dimethylformamide. The reaction can be carried out at ambient temperature.

In step (5) of Reaction Scheme III, a 3-amino-benzyloxy[1,5]naphthyridin-4-ol of Formula XXXIV is reacted with a carboxylic acid or an equivalent thereof to provide an amide of Formula XXXV. Suitable equivalents to carboxylic acid include acid anhydrides and acid chlorides. The reaction is conveniently carried out by adding the acid chloride to a solution of a 3-amino-benzyloxy[1,5]naphthyridin-4-ol of Formula XXXIV in a suitable solvent such as dichloromethane or acetonitrile in the presence of a tertiary amine such as triethylamine, pyridine, or 4-dimethylaminopyridine to afford an amide. The reaction can be carried out at or below ambient temperature.

In step (6) of Reaction Scheme III, a benzyloxy-[1,5]naphthyridin-4-ol of Formula XXXV is reacted with phosphorus pentasulfide to provide a benzyloxy-thiazolo[4,5-c][1,5]naphthyridine Formula XXXVI. The reaction can be carried out by adding phosphorus pentasulfide to a solution or suspension of a compound of Formula XXXV in a suitable solvent such as pyridine and heating the resulting mixture.

In step (7) of Reaction Scheme III, a benzyloxy-thiazolo[4,5-c][1,5]naphthyridine of Formula XXXVI is oxidized to provide a benzyloxy-thiazolo[4,5-c][1,5]naphthyridine-5N-oxide of Formula XXXVII using a conventional oxidizing agent capable of forming N-oxides. The reaction is conveniently carried out by adding 3-chloroperoxybenzoic acid to a solution of a compound of Formula XXXVI in a solvent such dichloromethane or chloroform. The reaction can be carried out at ambient temperature.

In step (8) of Reaction Scheme III, a benzyloxy-thiazolo[4,5-c][1,5]naphthyridine-5N-oxide of Formula XXXVII is aminated to provide a benzyloxy-thiazolo[4,5-c][1,5-naphthyridin-4-amine of Formula XXXVIII. Step (8) can be carried out by the activation of an N-oxide of Formula XXXVII by conversion to an ester and then reacting the ester with an aminating agent. Suitable activating agents include alkyl- or arylsulfonyl chlorides such as benzenesulfonyl chloride, methanesulfonyl chloride, or p-toluenesulfonyl chloride. Suitable aminating agents include ammonia, in the form of ammonium hydroxide, for example, and ammonium salts such as ammonium carbonate, ammonium bicarbonate, and ammonium phosphate. The reaction is conveniently carried out by adding ammonium hydroxide followed by p-toluenesulfonyl chloride to a solution of the N-oxide of Formula XXXVII in a suitable solvent such as 1,2-dichloroethane at elevated temperature. The reaction may be carried out by adding ammonium hydroxide and p-toluenesulfonyl chloride to the reaction mixture from step (7) without isolating the N-oxide of Formula XXXVII.

Alternatively step (8) can be carried out by the reaction of a benzyloxy-thiazolo[4,5-c][1,5]naphthyridine-5N-oxide of Formula XXXVII with trichloroacetyl isocyanate followed by hydrolysis of the resulting intermediate to provide a benzyloxy-thiazolo[4,5-c][1,5]naphthyridin-4-amine of Formula XXXVIII. The reaction is conveniently carried out in two steps by (i) adding trichloroacetyl isocyanate to a solution of the N-oxide of Formula XXXVII in a solvent such as dichloromethane and stirring at ambient temperature to provide an isolable amide intermediate. In step (ii), a solution of the intermediate in methanol is treated with a base such as sodium methoxide or ammonium hydroxide at ambient temperature.

In step (9) of Reaction Scheme III, the benzyl group of a benzyloxy-thiazolo[4,5-c][1,5]naphthyridin-4-amine of Formula XXXVIII is cleaved to provide a thiazolo[4,5-c][1,5]naphthyridinol of Formula XXXIX. The cleavage is conveniently carried out with an acid such as hydrogen bromide in a suitable solvent such as acetic acid at elevated temperature.

Alternatively, the cleavage may be carried out on a Parr apparatus under hydrogenolysis conditions using a suitable heterogeneous catalyst such as palladium on carbon in a solvent such as ethanol.

In step (10) of Reaction Scheme III a thiazolo[4,5-c][1,5]naphthyridinol of Formula XXXIX is converted to an ether-substituted thiazolo[4,5-c][1,5]naphthyridin-4-amine of Formula XXXX using a Williamson-type ether synthesis. The reaction is effected by treating a thiazolo[4,5-c][1,5]naphthyridinol of Formula XXXIX with an alkyl or aryl halide of Formula Halide-Z—Ar or Halide-Z—Ar′—Y—R₄in the presence of a base. Numerous reagents of Formulae Halide-Z—Ar and Halide-Z—Ar′—Y—R₄are commercially available, including substituted benzyl bromides and chlorides, substituted or unsubstituted arylalkylenyl bromides and chlorides, and substituted fluorobenzenes. Other reagents of Formulae Halide-Z—Ar and Halide-Z—Ar′—Y—R₄can be prepared using conventional synthetic methods. The reaction is conveniently carried out by combining a reagent of Formula Halide-Z—Ar or Halide-Z—Ar′—Y—R₄with a thiazolo[4,5-c][1,5]naphthyridinol of Formula XXXIX in a solvent such as DMF in the presence of a suitable base such as cesium carbonate. Optionally, catalytic tetrabutylammonium bromide can be added. The reaction can be carried out at ambient temperature or at an elevated temperature, for example 65° C. or 85° C., depending on the reactivity of the reagent of Formula Halide-Z—Ar or Halide-Z—Ar′—Y—R₄. The product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Alternatively, step (10) may be carried out using the Ullmann ether synthesis, in which an alkali metal aryloxide of a thiazolo[4,5-c][1,5]naphthyridinol of Formula XXXIX reacts with an aryl halide in the presence of copper salts, to provide compounds of Formula XXXX, where R₃is —Z—Ar or —Z—Ar′—Y—R₄, and Z is a bond.

embedded image

Compounds of the invention can also be prepared using the synthetic routes described in the EXAMPLES below.

Prodrugs can be prepared in a variety of ways. For example, a compound wherein R₂is hydroxyalkylenyl can be converted into a prodrug wherein R₂is, for example, -alkylenyl-O—C(R₆)—R₄, -alkylenyl-O—C(R₆)—O—R₄, or -alkylenyl-O—C(R₆)—N(R₈)—R₄, wherein R₄, R₆, and R₈are as defined above, using methods known to one skilled in the art. In addition, a compound wherein Ar is substituted by hydroxy or a hydroxyalkylenyl group may also be converted to an ester, an ether, a carbonate, or a carbamate. For any of these compounds containing an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as C_1-6alkanoyloxymethyl, 1-(C_1-6alkanoyloxy)ethyl, 1-methyl-1-(C_1-6alkanoyloxy)ethyl, C_1-6alkoxycarbonyloxymethyl, N—(C_1-6alkoxycarbonyl)aminomethyl, succinoyl, C_1-6alkanoyl, α-aminoC_1-4alkanoyl, arylacyl, —P(O)(OH)₂, —P(O)(O—C_1-6alkyl)₂, C_1-6alkoxycarbonyl, C_1-6alkylcarbamoyl, and α-aminoacyl or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independently selected from racemic, D-, and L-amino acids. For compounds containing an alcohol functional group, particularly useful prodrugs are esters made from carboxylic acids containing one to six carbon atoms, unsubstituted or substituted benzoic acid esters, or esters made from racemic, D-, or L-amino acids.

Prodrugs can also be made from a compound containing an amino group by conversion of the amino group to a functional group such as an amide, carbamate, urea, amidine, or another hydrolysable group using conventional methods. A prodrug of this type can be made by the replacement of a hydrogen atom in an amino group, particularly the amino group at the 4-position, with a group such as —C(O)—R′, α-aminoacyl, α-aminoacyl-α-aminoacyl, —C(O)—O—R′, —C(O)—N(R″)—R′, —CH(OH)—C(O)—OY′, —CH(OC_1-4alkyl)Y₀, —CH₂Y₁, or —CH(CH₃)Y₁; wherein R′ and R″ are each independently C_1-10alkyl, C_3-7cycloalkyl, or benzyl, each of which may be unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, hydroxy, nitro, cyano, carboxy, C_1-6alkyl, C_1-4alkoxy, aryl, heteroaryl, arylC_1-4alkylenyl, heteroarylC_1-4alkylenyl, haloC_1-4alkylenyl, haloC_1-4alkoxy, —O—C(O)—CH₃, —C(O)—O—CH₃, —C(O)—NH₂, —O—CH₂—C(O)—NH₂, —NH₂, and —S(O)₂—NH₂, with the proviso that R″ can also be hydrogen; each α-aminoacyl group is independently selected from racemic, D-, and L-amino acids; Y′ is hydrogen, C_1-6alkyl, or benzyl; Y₀is C_1-6alkyl, carboxyC_1-6alkylenyl, aminoC_1-4alkylenyl, mono-N—C_1-6alkylaminoC_1-4alkylenyl, or di-N,N—C_1-6alkylaminoC_1-4alkylenyl; and Y₁is mono-N—C_1-6alkylamino, di-N,N—C_1-6alkylamino, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, or 4-C_1-4alkylpiperazin-1-yl.

Pharmaceutical Compositions and Biological Activity

Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound or salt of the invention as described above in combination with a pharmaceutically acceptable carrier.

The terms “a therapeutically effective amount” and “effective amount” mean an amount of the compound or salt sufficient to induce a therapeutic or prophylactic effect, such as cytokine induction, immunomodulation, antitumor activity, and/or antiviral activity. Although the exact amount of active compound or salt used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound or salt, the nature of the carrier, and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about 100 nanograms per kilogram (ng/kg) to about 50 milligrams per kilogram (mg/kg), preferably about 10 micrograms per kilogram (μg/kg) to about 5 mg/kg, of the compound or salt to the subject. A variety of dosage forms may be used, such as tablets, lozenges, capsules, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like.

The compounds or salts of the invention can be administered as the single therapeutic agent in the treatment regimen, or the compounds or salts of the invention may be administered in combination with one another or with other active agents, including additional immune response modifiers, antivirals, antibiotics, antibodies, proteins, peptides, oligonucleotides, etc.

Compounds or salts of the invention have been shown to induce, and certain compounds or salts of the invention may inhibit, the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds or salts are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.

Cytokines whose production may be induced by the administration of compounds or salts of the invention generally include interferon-α (IFN-α) and/or tumor necrosis factor-α (TNF-α) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds or salts of the invention include IFN-α, TNF-α, IL-1, IL-6, IL-10 and IL-12, and a variety of other cytokines. Among other effects, these and other cytokines can inhibit virus production and tumor cell growth, making the compounds or salts useful in the treatment of viral diseases and neoplastic diseases. Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt or composition of the invention to the animal. The animal to which the compound or salt or composition is administered for induction of cytokine biosynthesis may have a disease as described infra, for example a viral disease or a neoplastic disease, and administration of the compound or salt may provide therapeutic treatment. Alternatively, the compound or salt may be administered to the animal prior to the animal acquiring the disease so that administration of the compound or salt may provide a prophylactic treatment.

In addition to the ability to induce the production of cytokines, compounds or salts of the invention can affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction. The compounds or salts may also activate macrophages, which in turn stimulate secretion of nitric oxide and the production of additional cytokines. Further, the compounds or salts may cause proliferation and differentiation of B-lymphocytes.

Compounds or salts of the invention can also have an effect on the acquired immune response. For example, the production of the T helper type 1 (T_H1) cytokine IFN-γ may be induced indirectly and the production of the T helper type 2 (T_H2) cytokines IL-4, IL-5 and IL-13 may be inhibited upon administration of the compounds or salts.

Other cytokines whose production may be inhibited by the administration of compounds or salts of the invention include tumor necrosis factor-α (TNF-α). Among other effects, inhibition of TNF-α production can provide prophylaxis or therapeutic treatment of TNF-α mediated diseases in animals, making the compounds or salt useful in the treatment of, for example, autoimmune diseases. Accordingly, the invention provides a method of inhibiting TNF-α biosynthesis in an animal comprising administering an effective amount of a compound or salt or composition of the invention to the animal. The animal to which the compound or salt or composition is administered for inhibition of TNF-α biosynthesis may have a disease as described infra, for example an autoimmune disease, and administration of the compound or salt may provide therapeutic treatment. Alternatively, the compound or salt may be administered to the animal prior to the animal acquiring the disease so that administration of the compound or salt may provide a prophylactic treatment.

Whether for prophylaxis or therapeutic treatment of a disease, and whether for effecting innate or acquired immunity, the compound or salt or composition may be administered alone or in combination with one or more active components as in, for example, a vaccine adjuvant. When administered with other components, the compound or salt and other component or components may be administered separately; together but independently such as in a solution; or together and associated with one another such as (a) covalently linked or (b) non-covalently associated, e.g., in a colloidal suspension.

Conditions for which compounds or salts identified herein may be used as treatments include, but are not limited to:

(a) viral diseases such as, for example, diseases resulting from infection by an adenovirus, a herpesvirus (e.g., HSV-I, HSV-II, CMV, or VZV), a poxvirus (e.g., an orthopoxvirus such as variola or vaccinia, or molluscum contagiosum), a picornavirus (e.g., rhinovirus or enterovirus), an orthomyxovirus (e.g., influenzavirus), a paramyxovirus (e.g., parainfluenzavirus, mumps virus, measles virus, and respiratory syncytial virus (RSV)), a coronavirus (e.g., SARS), a papovavirus (e.g., papillomaviruses, such as those that cause genital warts, common warts, or plantar warts), a hepadnavirus (e.g., hepatitis B virus), a flavivirus (e.g., hepatitis C virus or Dengue virus), or a retrovirus (e.g., a lentivirus such as HIV);

(b) bacterial diseases such as, for example, diseases resulting from infection by bacteria of, for example, the genus Escherichia, Enterobacter, Salmonella, Staphylococcus, Shigella, Listeria, Aerobacter, Helicobacter, Klebsiella, Proteus, Pseudomonas, Streptococcus, Chlamydia, Mycoplasma, Pneumococcus, Neisseria, Clostridium, Bacillus, Corynebacterium, Mycobacterium, Campylobacter, Vibrio, Serratia, Providencia, Chromobacterium, Brucella, Yersinia, Haemophilus, or Bordetella;

(c) other infectious diseases, such chlamydia, fungal diseases including but not limited to candidiasis, aspergillosis, histoplasmosis, cryptococcal meningitis, or parasitic diseases including but not limited to malaria, pneumocystis carnii pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis, and trypanosome infection;

(d) neoplastic diseases, such as intraepithelial neoplasias, cervical dysplasia, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, renal cell carcinoma, Kaposi's sarcoma, melanoma, leukemias including but not limited to myelogeous leukemia, chronic lymphocytic leukemia, multiple myeloma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, B-cell lymphoma, and hairy cell leukemia, and other cancers;

(e) T_H2-mediated, atopic diseases, such as atopic dermatitis or eczema, eosinophilia, asthma, allergy, allergic rhinitis, and Ommen's syndrome;

(f) certain autoimmune diseases such as systemic lupus erythematosus, essential thrombocythaemia, multiple sclerosis, discoid lupus, alopecia areata; and

(g) diseases associated with wound repair such as, for example, inhibition of keloid formation and other types of scarring (e.g., enhancing wound healing, including chronic wounds).

Additionally, a compound or salt of the present invention may be useful as a vaccine adjuvant for use in conjunction with any material that raises either humoral and/or cell mediated immune response, such as, for example, live viral, bacterial, or parasitic immunogens; inactivated viral, tumor-derived, protozoal, organism-derived, fungal, or bacterial immunogens; toxoids; toxins; self-antigens; polysaccharides; proteins; glycoproteins; peptides; cellular vaccines; DNA vaccines; autologous vaccines; recombinant proteins; and the like, for use in connection with, for example, BCG, cholera, plague, typhoid, hepatitis A, hepatitis B, hepatitis C, influenza A, influenza B, parainfluenza, polio, rabies, measles, mumps, rubella, yellow fever, tetanus, diphtheria, hemophilus influenza b, tuberculosis, meningococcal and pneumococcal vaccines, adenovirus, HIV, chicken pox, cytomegalovirus, dengue, feline leukemia, fowl plague, HSV-1 and HSV-2, hog cholera, Japanese encephalitis, respiratory syncytial virus, rotavirus, papilloma virus, yellow fever, and Alzheimer's Disease.

Compounds or salts of the present invention may be particularly helpful in individuals having compromised immune function. For example, compounds or salts may be used for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIV patients.

Thus, one or more of the above diseases or types of diseases, for example, a viral disease or a neoplastic disease may be treated in an animal in need thereof (having the disease) by administering a therapeutically effective amount of a compound or salt of the invention to the animal.

An amount of a compound or salt effective to induce or inhibit cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN-α, TNF-α, IL-1, IL-6, IL-10 and IL-12 that is increased (induced) or decreased (inhibited) over a background level of such cytokines. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 μg/kg to about 5 mg/kg. The invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound or salt or composition of the invention to the animal. An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise amount that is effective for such treatment will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 μg/kg to about 5 mg/kg. An amount of a compound or salt effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 μg/kg to about 5 mg/kg.

In addition to the formulations and uses described specifically herein, other formulations, uses, and administration devices suitable for compounds of the present invention are described in, for example, International Publication Nos. WO 03/077944 and WO 02/036592, U.S. Pat. No. 6,245,776, and U.S. Publication Nos. 2003/0139364, 2003/185835, 2004/0258698, 2004/0265351, 2004/076633, and 2005/0009858.

EXAMPLES

Objects and advantages of this invention are further illustrated by the following examples, but the particular materials and amounts thereof recited in these examples, as well as other conditions and details, should not be construed to unduly limit this invention.

Example 1
7-Benzyloxy-2-propylthiazolo[4,5-c]quinolin-4-amine

embedded image

Part A

A mixture of triethyl orthoformate (92 mL, 0.55 mol) and 2,2-dimethyl-[1,3]-dioxane-4,6-dione (75.3 g, 0.522 mol) (Meldrum's acid) was heated at 55° C. for 90 minutes and then cooled to 45° C. A solution of 3-benzyloxyaniline (100.2 g, 0.5029 mol) in methanol (200 mL) was slowly added to the reaction over a period 45 minutes while maintaining the reaction temperature below 50° C. The reaction was then heated at 45° C. for one hour, allowed to cool to room temperature, and stirred overnight. The reaction mixture was cooled to 1° C., and the product was isolated by filtration and washed with cold ethanol (˜400 mL) until the filtrate was colorless. 5-{[(3-Benzyloxy)phenylimino]methyl}-2,2-dimethyl-[1,3]-dioxane-4,6-dione (170.65 g) was isolated as a tan, powdery solid. ¹H NMR (300 MHz, DMSO-d₆) δ 11.21 (d, J=14.2 Hz, 1H), 8.61 (d, J=14.2 Hz, 1H), 7.49-7.30 (m, 7H), 7.12 (dd, J=8.1, 1.96 Hz, 1H), 6.91 (dd, J=8.4, 2.1 Hz, 1H), 5.16 (s, 2H), 1.68 (s, 6H).

Part B

A mixture of 5-{[(3-benzyloxy)phenylimino]methyl}-2,2-dimethyl-[1,3]-dioxane-4,6-dione (170.65 g, 0.483 mol) and DOWTHERM A (800 mL) was heated to 100° C. and then slowly added to a flask containing DOWTHERM A (1.3 L, heated at 210° C.) over a period of 40 minutes. During the addition, the reaction temperature was not allowed to fall below 207° C. Following the addition, the reaction was stirred at 210° C. for one hour, and then allowed to cool to ambient temperature. A precipitate formed, which was isolated by filtration, washed with diethyl ether (1.7 L) and acetone (0.5 L), and dried in an oven to provide 76.5 g of 7-benzyloxyquinolin-4-ol as a tan powder. ¹H NMR (300 MHz, DMSO-d₆) δ 11.53 (s, 1H), 7.99 (dd, J=2.4, 7.4 Hz, 1H), 7.79 (d, J=7.4 Hz, 1H), 7.50-7.32 (m, 5H), 7.00 (s, 1H), 6.98 (dd, J=2.5, 7.4 Hz, 1H), 5.93 (d, J=7.5 Hz, 1H), 5.20 (s, 2H).

Part C

A mixture of 7-benzyloxyquinolin-4-ol (71.47 g, 0.2844 mol) and propionic acid (700 mL) was heated to 125° C. with vigorous stirring. Nitric acid (23.11 mL of 16 M) was slowly added over a period of 30 minutes while maintaining the reaction temperature between 121° C. and 125° C. After the addition, the reaction was stirred at 125° C. for 1 hour then allowed to cool to ambient temperature. The resulting solid was isolated by filtration, washed with water, and dried in an oven for 1.5 days to provide 69.13 g of 7-benzyloxy-3-nitroquinolin-4-ol as a grayish powder. ¹H NMR (300 MHz, DMSO-d₆) δ 12.77 (s, 1H), 9.12 (s, 1H), 8.17 (dd, J=3.3, 6.3 Hz, 1H), 7.51-7.33 (m, 5H), 7.21-7.17 (m, 2H), 5.25 (s, 2H).

Part D

A mixture of 7-benzyloxy-3-nitroquinolin-4-ol (10.67 g, 36.0 mmol) and 5% platinum on carbon (1.05 g) in N,N-dimethylformamide (DMF, 110 mL) was hydrogenated on a Parr apparatus. The mixture was filtered through CELITE filter agent. The CELITE filter agent was rinsed with DMF (20 mL). The filtrate was cooled in an ice bath and acidified with hydrogen chloride gas, resulting in the formation of a reddish-brown solid. The solid was isolated by filtration, washed with acetone, and dried in a vacuum oven at 60° C. to provide 3-amino-7-benzyloxyquinolin-4-ol hydrochloride as a tan solid (8.17 g, 75%).

Part E

To a solution of the crude 3-amino-7-benzyloxyquinolin-4-ol hydrochloride (8.03 g, 26.5 mmol) prepared in Part D and triethylamine (7.40 mL, 53 mmol) in dichloromethane at 0° C. was added butyryl chloride (2.75 mL, 26.5 mmol) dropwise via syringe. The solution was stirred at 0° C. for 10 minutes (min), then the cooling bath was removed. A solid formed that was isolated by filtration and washed with a small amount of dichloromethane. The solid was slurried with water (75 mL) and was isolated by filtration. The solid was rinsed with water followed by ether, then dried at 60° C. in a vacuum oven to provide 8.03 g (90%) of the crude product, N-(7-benzyloxy-4-hydroxyquinolin-3-yl)butyramide, which was contaminated with a salt of triethylamine as determined by ¹H NMR analysis.

Part F

A mixture of the N-(7-benzyloxy-4-hydroxyquinolin-3-yl)butyramide prepared in Part E (2.97 g, 8.83 mmol), P₂S₅(1.96 g, 4.41 mmol), and pyridine was placed under a nitrogen atmosphere and heated to reflux. The resulting solution was cooled and the excess P₂S₅was quenched slowly with 10% aqueous Na₂CO₃(10 mL). The reaction mixture was partitioned between water (40 mL) and CH₂Cl₂(100 mL). The organic layer was washed with 0.1 M aqueous HCl (50 mL), dried over MgSO₄, filtered and concentrated to yield a brownish-yellow solid. The solid was treated with boiling heptane (40 mL) and filtered. The filtrate was allowed to cool and a solid formed. The light yellow solid was isolated by filtration and washed with cold heptane to provide 7-benzyloxy-2-propylthiazolo[4,5-c]quinoline (1.74 g, 59%).

Part G

To a solution of 7-benzyloxy-2-propylthiazolo[4,5-c]quinoline (4.89 g, 14.6 mmol) in CH₂Cl₂(75 mL) at room temperature (rt) was added 3-chloroperoxybenzoic acid (m-CPBA, 65% w/w, 5.82 g, 21.93 mmol) in portions. After one hour (h), the mixture was transferred to a separatory funnel and washed with 10% aqueous Na₂CO₃(2×50 mL). The aqueous layer was extracted with CH₂Cl₂(50 mL). The combined organic layers were washed with water (75 mL), dried over MgSO₄, filtered, concentrated, and dried under high vacuum to yield 7-benzyloxy-2-propylthiazolo[4,5-c]quinoline-5N-oxide as a light yellow solid (4.93 g, 96%).

Part H

To a light orange solution of 7-benzyloxy-2-propylthiazolo[4,5-c]quinoline-5N-oxide (4.93 g, 14.1 mmol) in CH₂Cl₂(100 mL) at 0° C. was added trichloroacetylisocyanate (2.00 mL, 16.9 mmol). The solution was allowed to warm to rt and was stirred 20 h. The solution was concentrated in vacuo, and the resulting residue N-(7-benzyloxy-2-propylthiazolo[4,5-c]quinolin-4-yl)-2,2,2-trichloroacetamide was used without further manipulation in the next step.

Part I

To a magnetically stirred mixture of N-(7-benzyloxy-2-propylthiazolo[4,5-c]quinolin-4-yl)-2,2,2-trichloroacetamide (prepared as described above in Part H, 6.96 g, 14.9 mmol) in methanol (100 mL) at rt was added NaOMe (25 wt. % solution in MeOH, 11.3 mL, 52.1 mmol). After a few minutes a solution formed from which a solid precipitated. The reaction mixture was concentrated in vacuo and dried under vacuum. The resulting solid was suspended in a minimal amount of methanol (50 mL) and was isolated by filtration. The solid was washed with methanol to provide 7-benzyloxy-2-propylthiazolo[4,5-c]quinolin-4-amine as a light yellow solid in high purity (3.93 g, 76%), mp 175-178° C. ¹H NMR (300 MHz, d₆-DMSO) δ 7.67 (d, J=8.7 Hz, 1H), 7.49-7.29 (m, 5H), 7.10 (d, J=2.5 Hz, 1H), 6.96 (dd, J=8.7, 2.5 Hz, 1H), 6.84 (s, 2H), 5.20 (s, 2H), 3.09 (t, J=7.8 Hz, 2H), 1.84 (sextet, J=7.2 Hz, 2H), 0.99 (t, J=7.5 Hz, 3H); ¹³C NMR (75 MHz, d₆-DMSO) δ 169.1, 158.9, 152.4, 146.5, 139.4, 137.0, 136.0, 128.4, 127.8, 127.6, 125.7, 113.3, 113.2, 107.8, 69.3, 35.1, 22.8, 13.5. MS (APCI) m/z=350.0 (M+H) % Anal. calcd for C₂₀H₁₉N₃OS: C, 68.74; H, 5.48; N, 12.02. Found: C, 68.62; H, 5.74; N, 11.94.

Example 2
7-(4-Fluorobenzyloxy)-2-propylthiazolo[4,5-c]quinolin-4-amine

embedded image

Part A

To 7-benzyloxy-2-propylthiazolo[4,5-c]quinoline (prepared as described in Part F of Example 1, 4.52 g, 13.5 mmol) was added a 45 wt. % solution of hydrogen bromide in acetic acid (40 mL). The resulting solution was heated at 65° C. for 1.5 h, then cooled in an ice bath. Aqueous NaOH (50% w/w solution) was added slowly until the pH=7 and a light yellow solid formed. The solid was isolated by filtration, dried, and then suspended in boiling ethanol (25 mL) for 5 min. The mixture was allowed to cool to rt and a tan solid was isolated by filtration. The solid was washed with cold ethanol and dried in a vacuum oven to yield 7-hydroxy-2-propylthiazolo[4,5-c]quinoline (2.69 g, 82%).

Part B

A mixture of 7-hydroxy-2-propylthiazolo[4,5-c]quinoline (0.88 g, 3.6 mmol) and cesium carbonate (2.35 g, 7.20 mmol) in DMF (50 mL) was stirred for 30 min, then 4-fluorobenzylbromide (0.50 mL, 4.0 mmol) was added. After 2 h, the mixture was concentrated in vacuo to remove the DMF. The resulting solid was partitioned between dichloromethane (100 mL) and water (100 mL). The organic layer was washed with water (50 mL) and brine (50 mL), dried over MgSO₄, filtered, and concentrated to a light yellow solid. The solid was recrystallized from heptane and pure 7-(4-fluorobenzyloxy)-2-propylthiazolo[4,5-c]quinoline was isolated as a tan solid (0.86 g, 68%).

Part C

7-(4-Fluorobenzyloxy)-2-propylthiazolo[4,5-c]quinoline (0.84 g, 2.38 mmol) was treated with m-CPBA (65% w/w, 0.95 g, 3.58 mmol) according to the method described in Part G of Example 1 to yield 7-(4-fluorobenzyloxy)-2-propylthiazolo[4,5-c]quinoline-5N-oxide as a light yellow solid (0.81 g, 92%).

Part D

To a solution of 7-(4-fluorobenzyloxy)-2-propylthiazolo[4,5-c]quinoline-5N-oxide (0.81 g, 2.2 mmol) in 1,2-dichloroethane at 65° C. in a glass heavy wall pressure vessel was added concentrated ammonium hydroxide (5 mL) and p-toluenesulfonyl chloride (0.42 g, 2.4 mmol). The vessel was sealed with a screw cap and the mixture was stirred at 65° C. for 3 h. The reaction mixture was transferred to a separatory funnel with dichloromethane (50 mL) and washed with 2 M aqueous Na₂CO₃(2×50 mL). The combined aqueous layers were extracted with dichloromethane (50 mL). The organic phases were combined, washed with water (50 mL) and brine (50 mL), dried over MgSO₄, filtered and concentrated to yield a brown solid. The crude product was purified on a HORIZON High-Performance Flash Chromatography (HPFC) instrument (available from Biotage, Inc, Charlottesville, Va., USA) (silica gel eluting sequentially with 0-15% of a solution comprised of 80% CHCl₃, 18% MeOH, and 2% conc. NH₄OH(CMA) in chloroform). The appropriate fractions were combined and concentrated to provide a light yellow solid. The solid was crystallized from acetonitrile. The resulting white solid was isolated, washed with acetonitrile, and dried overnight at 60° C. in a vacuum oven to provide 7-(4-fluorobenzyloxy)-2-propylthiazolo[4,5-c]quinolin-4-amine (0.33 g, 41%), mp 189-192° C. NMR (300 MHz, d₆-DMSO) δ 7.67 (d, J=8.8 Hz, 1H), 7.55-7.50 (m, 2H), 7.26-7.18 (m, 2H), 7.10 (d, J=2.5 Hz, 1H), 6.96 (dd, J=8.8, 2.5 Hz, 1H), 6.80 (s, 2H), 5.20 (s, 2H), 3.11 (t, J=7.8 Hz, 2H), 1.84 (sextet, J=7.2 Hz, 2H), 1.00 (t, J=7.5 Hz, 3H); Anal. calcd for C₂₀H₁₈N₃OSF: C, 65.38; H, 4.94; N, 11.44. Found: C, 65.36; H, 4.87; N, 11.39.

Example 3
7-[2-(4-Fluorophenyl)ethoxy]-2-propylthiazolo[4,5-c]quinolin-4-amine

embedded image

Part A

Iodine (12.0 g, 47.4 mmol) was added in one portion to a solution of 2-phenylethanol (5.11 g, 36.5 mmol), triphenylphosphine (11.47 g, 43.8 mmol) and imidazole (3.48 g, 51.04 mmol) in dichloromethane (250 mL) at 0° C. The resulting mixture was allowed to warm slowly to rt and stir overnight, then was transferred to a separatory funnel and washed with water (2×250 mL), saturated aqueous Na₂S₂O₃(2×100 mL), water (100 mL), and brine (100 mL). The organic phase was dried over MgSO₄, filtered and concentrated to a colorless oil that contained a large amount of white solid. The mixture was treated with heptane (2×50 mL) and was filtered. The filtrate was concentrated and the resulting material was again treated with heptane (2×50 mL) and filtered. The filtrate was concentrated to provide 2-phenylethyl iodide as a clear colorless oil (1.74 g, 19%) that contained a trace amount of triphenylphosphine oxide.

Part B

A mixture of 7-hydroxy-2-propylthiazolo[4,5-c]quinoline (prepared as described in Part A of Example 2, 0.94 g, 3.9 mmol) and cesium carbonate (2.07 g, 6.36 mmol) in DMF (25 mL) was heated at 75° C. for 20 min, then a solution of 2-phenylethyl iodide (1.06 g, 4.24 mmol) in DMF (10 mL) was added dropwise. The solution was heated at 75° C. for 4 d. The DMF was removed in vacuo and the resulting solid was partitioned between chloroform (100 mL) and water (100 mL). The organic layer was washed with water (50 mL) and brine (50 mL), dried over MgSO₄, filtered, and concentrated to a dark brown solid. The solid was purified by HPFC (silica gel eluting sequentially with 0-8% CMA in chloroform). The appropriate fractions were combined and concentrated to provide 7-[2-(4-fluorophenyl)ethoxy]-2-propylthiazolo[4,5-c]quinoline as a light yellow solid (0.27 g, 19%).

Part C

7-[2-(4-Fluorophenyl)ethoxy]-2-propylthiazolo[4,5-c]quinoline (0.29 g, 0.79 mmol) was treated with m-CPBA (65% w/w, 0.32 g, 1.2 mmol) according to the method described in Part G of Example 1 to yield 7-[2-(4-fluorophenyl)ethoxy]-2-propylthiazolo[4,5-c]quinoline-5N-oxide as a light orange solid (0.30 g, 100%).

Part D

7-[2-(4-Fluorophenyl)ethoxy]-2-propylthiazolo[4,5-c]quinoline-5N-oxide (0.30 g, 0.78 mmol) was treated with concentrated ammonium hydroxide (4 mL) and p-toluenesulfonyl chloride (0.17 g, 0.86 mmol) according to the method described in Part D of Example 2. The crude product was purified by HPFC (silica gel eluting sequentially with 0-15% CMA in chloroform). The appropriate fractions were combined and concentrated to provide a light yellow solid. The solid was crystallized from acetonitrile. The resulting white solid was isolated, washed with acetonitrile, and dried overnight at 60° C. in a vacuum oven to provide 7-[2-(4-fluorophenyl)ethoxy]-2-propylthiazolo[4,5-c]quinolin-4-amine (0.13 g, 43%), mp 145-148° C. ¹H NMR (300 MHz, d₆-DMSO) δ 7.67 (d, J=8.7 Hz, 1H), 7.40-7.34 (m, 2H), 7.17-7.09 (m, 2H), 7.03 (d, J=2.5 Hz, 1H), 6.87 (dd, J=8.8, 2.5 Hz, 1H), 6.79 (s, 2H), 4.27 (t, J=6.5 Hz, 2H), 3.11 (t, J=7.8 Hz, 2H), 3.06 (t, J=6.6 Hz, 2H), 1.82 (sextet, J=7.2 Hz, 2H), 1.00 (t, J=7.5 Hz, 3H); Anal. calcd for C₂₁H₂₀N₃OSF: C, 66.12; H, 5.28; N, 11.02. Found: C, 66.19; H, 5.26; N, 11.03.

Example 4
7-[2-(Benzyloxy)ethoxy]-2-propylthiazolo[4,5-c]quinolin-4-amine

embedded image

Part A

A solution of 2-(benzyloxy)ethanol (5.12 g, 33.6 mmol), triphenylphosphine (10.59 g, 40.4 mmol), and imidazole (3.21 g, 47.1 mmol) in dichloromethane (250 mL) was treated with iodine (11.10 g, 43.7 mmol) according to the method described in Part A of Example 3 to yield benzyl 2-iodomethyl ether as a clear colorless oil (5.95 g, 68%) that contained a trace amount of triphenylphosphine oxide.

Part B

A mixture of 7-hydroxy-2-propylthiazolo[4,5-c]quinoline (prepared as described in Part A of Example 2, 0.66 g, 2.7 mmol) and cesium carbonate (1.32 g, 4.05 mmol) in DMF (25 mL) was heated at 75° C. for 30 min, then a solution of benzyl 2-iodomethyl ether (1.42 g, 5.40 mmol) in DMF (5 mL) was added dropwise. The solution was heated at 75° C. for 16 h. The DMF was removed in vacuo and the resulting solid was partitioned between chloroform (100 mL) and water (100 mL). The organic layer was washed with water (50 mL) and brine (50 mL), dried over MgSO₄, filtered, and concentrated to a dark brown solid. The solid was purified by HPFC (silica gel eluting sequentially with 0-8% CMA in chloroform). The appropriate fractions were combined and concentrated to provide 7-[2-(benzyloxy)ethoxy]-2-propylthiazolo[4,5-c]quinoline as a light yellow solid (0.89 g, 87%).

Part C

7-[2-(Benzyloxy)ethoxy]-2-propylthiazolo[4,5-c]quinoline (0.89 g, 2.35 mmol) was treated with m-CPBA (65% w/w, 0.94 g, 3.53 mmol) according to the method described in Part G of Example 1 to yield 7-[2-(benzyloxy)ethoxy]-2-propylthiazolo[4,5-c]quinoline-5N-oxide as a light yellow solid (0.85 g, 91%).

Part D

7-[2-(Benzyloxy)ethoxy]-2-propylthiazolo[4,5-c]quinoline-5N-oxide (0.85 g, 2.15 mmol) was treated with concentrated ammonium hydroxide (5 mL) and p-toluenesulfonyl chloride (0.45 g, 2.37 mmol) according to the method described in Part D of Example 2. The crude product was purified by HPFC (silica gel eluting sequentially with 0-15% CMA in chloroform). The appropriate fractions were combined and concentrated to provide a light yellow solid. The solid was crystallized from acetonitrile. The resulting white solid was isolated by filtration, washed with acetonitrile, and dried overnight at 60° C. in a vacuum oven to provide 7-[2-(benzyloxy)ethoxy]-2-propylthiazolo[4,5-c]quinolin-4-amine (0.29 g, 34%) as off-white needles, mp 142-145° C. ¹H NMR (300 MHz, d₆-DMSO) δ 7.67 (d, J=8.8 Hz, 1H), 7.37-7.24 (m, 5H), 7.04 (d, J=2.5 Hz, 1H), 6.90 (dd, J=9.0, 2.8 Hz, 1H), 6.80 (s, 2H), 4.57 (s, 2H), 4.24-4.21 (m, 2H), 3.82-3.79 (m, 2H), 3.11 (t, J=7.2 Hz, 2H), 1.84 (sextet, J=7.2 Hz, 2H), 1.00 (t, J=7.5 Hz, 3H); ¹³C NMR (75 MHz, d₆-DMSO) δ 169.0, 159.1, 152.4, 146.5, 139.36, 138.3, 136.0, 128.2, 127.5, 127.4, 125.7, 113.1, 107.3, 72.1, 68.2, 67.1, 35.1, 22.8, 13.4; Anal. calcd for C₂₂H₂₃N₃O₂S: C, 67.15; H, 5.89; N, 10.68. Found: C, 67.11; H, 5.77; N, 10.48.

Example 5
7-(Furan-3-ylmethyloxy)-2-propylthiazolo[4,5-c]quinolin-4-amine

embedded image

Part A

Diisopropyl azodicarboxylate (1.51 g, 7.5 mmol) was added to a mixture of 7-hydroxy-2-propylthiazolo[4,5-c]quinoline (prepared as described in Part A of Example 2, 920 mg, 3.76 mmol) and triphenylphosphine (1.96 g, 7.5 mmol) in THF (50 mL). The mixture was stirred overnight. The following morning, additional reagents were added to the solution and stirring was continued for 3 h. The solvent was removed in vacuo and the residue was dissolved in dichloromethane and washed with 2% aqueous Na₂CO₃(3×50 mL). The aqueous phases were combined and extracted multiple times with chloroform. The organic phases were combined, dried over MgSO₄, filtered, and concentrated. The crude product was purified by HPFC (silica gel eluting with a dichloromethane/methanol gradient). All fractions containing the product 7-(furan-3-ylmethyloxy)-2-propyl-thiazolo[4,5-c]quinoline were combined, concentrated, and carried on to the next step without further purification.

Part B

7-(Furan-3-ylmethyloxy)-2-propylthiazolo[4,5-c]quinoline (prepared as described above in Part A, 3.76 mmol) was treated with m-CPBA (60% w/w, 1.60 g, 5.65 mmol) according to the method described in Part G of Example 1 to yield 7-(furan-3-ylmethyloxy)-2-propyl-thiazolo[4,5-c]quinoline-5N-oxide as a solid. The solid was dissolved in dichloromethane (100 mL) and trichloroacetyl isocyanate (777 mg, 4.13 mmol) was added dropwise to the solution. After all the starting material was consumed in the reaction, concentrated ammonium hydroxide (2 mL) was added. After several minutes the mixture was concentrated in vacuo and the residue was purified by HPFC (silica gel with a gradient elution using 0-15% CMA in chloroform). The appropriate fractions were combined and concentrated to a solid. The solid was dissolved in dichloromethane and loaded onto an acid ion-exchange resin. The resin was washed with methanol (2×40 mL). The 7-(furan-3-ylmethyloxy)-2-propylthiazolo[4,5-c]quinolin-4-amine was eluted with a solution of 2 M ammonia in methanol (2×40 mL). The filtrate was concentrated in vacuo and pure 7-(furan-3-ylmethyloxy)-2-propylthiazolo[4,5-c]quinolin-4-amine was obtained as an off-white crystals, mp 170.0-171.0° C. (143 mg, 12%) after crystallization from acetonitrile. MS (APCI) m/z 340 (M+H)⁺; Anal. calcd for C₁₈H₁₇N₃O₂S: C, 63.70; H, 5.05; N, 12.38. Found: C, 63.38; H, 5.08; N, 12.56.

Examples 6-28

To 7-benzyloxy-2-propylthiazolo[4,5-c]quinolin-4-amine (prepared as described in Example 1, 1.59 g, 4.55 mmol) was added a 30 wt. % solution of hydrogen bromide in acetic acid (25 mL). The resulting solution was heated at 65° C. for 1 h, then cooled in an ice bath. Aqueous NaOH (50% w/w solution) was added slowly until the pH=7 and a light yellow solid formed. The solid was isolated by filtration, dried, and purified by HPFC (silica gel eluting sequentially with 0-10% of a solution comprised of 80% CHCl₃, 18% MeOH, and 2% conc. NH₄OH (CMA) in chloroform, then 10-35% CMA in chloroform). The appropriate fractions were concentrated to a light yellow solid that was crystallized from toluene containing a small amount of methanol. The light yellow solid was isolated by filtration, washed with cold toluene, and dried at 60° C. in a vacuum oven to provide the acetic acid salt of 7-hydroxy-2-propylthiazolo[4,5-c]quinolin-4-amine (0.64 g, 54%), mp 236-239° C. ¹H NMR (300 MHz, d₆-DMSO) δ 9.72 (s, 1H), 7.58 (d, J=8.8 Hz, 1H), 6.91 (d, J=2.2 Hz, 1H), 6.78 (dd, J=8.7, 2.2 Hz, 1H), 6.70 (s, 2H), 3.12 (t, J=7.8 Hz, 2H), 1.83 (sextet, J=7.2 Hz, 2H), 0.99 (t, J=7.5 Hz, 3H); ¹³C NMR (75 MHz, d₆-DMSO) δ 168.4, 158.1, 152.2, 146.6, 139.6, 135.6, 125.7, 113.3, 112.2, 108.9, 35.0, 22.8, 13.4; Anal. calcd for C₁₃H₁₃N₃OS.0.22C₂H₄O₂: C, 59.23; H, 5.13; N, 15.42. Found: C, 59.42; H, 5.00; N, 15.41.

Aliquots (1 mL, 0.1 mmol) of an anhydrous dimethylformamide solution (39 mL) of 7-hydroxy-2-propylthiazolo[4,5-c]quinolin-4-ylamine (1.01 g, 3.9 mmol) were transferred to test tubes containing anhydrous potassium carbonate (55 mg, 0.4 mmol). Appropriate amounts of the alkylating agents (1.1 equivalents) listed below were added to the test tubes and the test tubes were shaken overnight. A filtration plate was used to remove the potassium carbonate from the reaction mixtures and the filtrates were collected in a 2.2 mL/well titre plate. The solvent was removed by vacuum centrifugation. The compounds were purified by preparative high performance liquid chromatography (prep HPLC) using a Waters Fraction Lynx automated purification system. The prep HPLC fractions were analyzed using a Micromass LC/TOF-MS, and the appropriate fractions were centrifuge evaporated to provide the trifluoroacetate salt of the desired compound. Column: Zorbax BonusRP, 21.2×50 millimeters (mm), 5 micron particle size; non-linear gradient elution from 5-95% B where A is 0.05% trifluoroacetic acid/water and B is 0.05% trifluoroacetic acid/acetonitrile; fraction collection by mass-selective triggering. The table below shows the reagent used for each example, the structure of the resulting compound, and the observed accurate mass for the isolated trifluoroacetate salt.

Measured

Ex-

Mass

ample
Reagent
R₃
(M + H)

6
Benzyl bromide

embedded image

350.1351

7
α-Bromo-m-xylene

embedded image

364.1489

8
2-Cyanobenzyl bromide

embedded image

375.1294

9
2-Chlorobenzyl bromide

embedded image

384.0940

10
3-Chlorobenzyl bromide

embedded image

384.0964

11
2,3-Difluorobenzyl bromide

embedded image

386.1135

12
2,4-Difluorobenzyl bromide

embedded image

386.1138

13
2,6-Difluorobenzyl bromide

embedded image

386.1146

14
3,4-Difluorobenzyl bromide

embedded image

386.1156

15
4-Nitrobenzyl bromide

embedded image

395.1208

16
4-(Trifluoromethyl)benzyl bromide

embedded image

418.1194

17
2-(Trifluoromethyl)benzyl bromide

embedded image

418.1221

18
3-(Trifluoromethyl)benzyl bromide

embedded image

418.1209

19
2,6-Dichlorobenzyl bromide

embedded image

418.0553

20
3-(Trifluoromethoxy)benzyl bromide

embedded image

434.1153

21
(1-Bromoethyl)benzene

embedded image

364.1512

22
α-Bromo-o-xylene

embedded image

364.1486

23
4-Cyanobenzyl bromide

embedded image

375.1289

24
4-Chlorobenzyl bromide

embedded image

384.0956

25
2-(Bromomethyl)-5-nitrofuran

embedded image

385.0987

26
2-(Bromomethyl)naphthalene

embedded image

400.1487

27
Methyl 4- (bromomethyl)benzoate

embedded image

408.1399

28
Methyl alpha- bromophenylacetate

embedded image

408.1386

Example 29
7-Benzyloxy-2-ethylthiazolo[4,5-c]quinolin-4-amine

embedded image

Part A

A 1 L glass Parr bottle was charged with 7-benzyloxy-3-nitroquinolin-7-ol, anhydrous N,N-dimethylformamide (DMF, 500 mL) and 5% Pt/C catalyst (5.0 g). The vessel was placed on Parr apparatus, evacuated and charged with hydrogen gas (˜45 psi, 3.1×10⁵Pa). The reaction mixture was shaken overnight. The reaction mixture was filtered through glass fiber filters to remove catalyst. To the resulting dark colored solution was added concentrated hydrochloric acid (12 N HCl, 14 ml, 168.8 mmol). The product precipitated as the hydrochloride salt. The reaction mixture was stirred over the weekend. A solid was collected by vacuum filtration, washed with diethyl ether (100 mL), and air dried overnight to provide 44 g of 3-amino-7-benzyloxyquinolin-4-ol hydrochloride. This material was carried on without further purification.

Part B

To a stirred solution of 3-amino-7-benzyloxyquinolin-4-ol hydrochloride (40.4 g, 133.4 mmol), and triethylamine (2.5 eq., 33.8 g, 333.6 mmol) in dichloromethane (1000 mL) at room temperature, was slowly added propionyl chloride (1.1 eq., 13.6 g, 146.8 mmol). After 6 hours the reaction was quenched with water (250 ml). The reaction mixture was transferred to a separatory funnel and the layers were separated. The dichloromethane layer was concentrated to provide 41.5 g of N-(7-benzyloxy-4-hydroxyquinolin-3-yl)propionamide as a pale tan crystalline solid. MS (ACPI) m/z=323 (M+H)⁺. This material was carried on without further purification to the next step.

Part C

To a stirred slurry of N-(7-benzyloxy-4-hydroxyquinolin-3-yl)propionamide in pyridine 500 (mL) was added 0.5 eq. phosphorous pentasulfide (28.6 g, 64.4 mmol). The reaction mixture was heated to reflux. The reaction mixture became homogeneous (dark orange) as the reaction heated to reflux. The reaction was maintained at reflux overnight. The reaction mixture was cooled to room temperature and the excess phosphorous pentasulfide was slowly quenched with 10% aqueous sodium carbonate (50 mL). The reaction mixture was transferred to a separatory funnel and partitioned between water (200 mL) and dichloromethane (700 mL). The layers were separated. The aqueous layer was extracted with dichloromethane (3×100 mL). The organic layers were combined and concentrated to dryness. The resulting tan solid was treated with boiling heptane (3×400 mL) and filtered. The heptane filtrates were combined and concentrated to provide 15 g of 7-benzyloxy-2-ethylthiazolo[4,5-c]quinoline as a pale yellow crystalline solid. MS (ACPI) m/z=321 (M+H)⁺. This material was carried on without further purification to the next step.

Part D

To a stirred solution of 7-benzyloxy-2-ethylthiazolo[4,5-c]quinoline (15.0 g, 46.8 mmol) in chloroform (150 mL), 3-chloroperoxybezoic acid (m-CPBA. 50% w/w, 16.15 g, 46.8 mmol) was slowly added in small portions. The reaction was maintained at room temperature overnight. The reaction mixture was transferred to a separatory funnel and washed with 10% aqueous sodium carbonate (2×50 mL). The chloroform layer was concentrated to provide 15.4 g of 7-benzyloxy-2-ethylthiazolo[4,5-c]quinoline 5-oxide as a light tan solid. MS (ACPI) m/z=337 (M+H)⁺. This material was carried on without further purification to the next step.

Part E

To a vigorously stirred pale orange solution of 7-benzyloxy-2-ethylthiazolo[4,5-c]quinoline 5-oxide (15.00 g, 44.6 mmol) in dichloromethane (200 mL), at room temperature, was slowly added trichloroacetylisocyanate (1.05 eq., 5.6 ml 46.8 mmol). The solution was maintained at room temperature for 18 hours. At this time the reaction was quenched by the addition of concentrated ammonium hydroxide solution (60 ml). An off-white precipitate formed and was collected by vacuum filtration. Recrystallization from acetonitrile provided 11.3 g of 7-benzyloxy-2-ethylthiazolo[4,5-c]quinolin-4-amine as a white crystalline solid, mp 208-209° C. MS (APCI) m/z 336.1 (M+H)⁺; Anal. calcd for C₁₉H₁₇N₃OS: C, 68.03; H, 5.11; N, 12.53. Found: C, 67.45; H, 4.83; N, 12.41.

Example 30
2-Ethyl-7-[3-(pyridin-3-yl)propoxy]thiazolo[4,5-c]quinolin-4-amine

embedded image

Part A

To a round bottom flask containing 7-benzyloxy-2-ethylthiazolo[4,5-c]quinolin-4-amine (11.3 g, 33.7 mmol) was added a 45 wt. % solution of hydrogen bromide in acetic acid (40 mL). The resulting solution was heated at 65° C. for 2 hours and then cooled in an ice bath. Aqueous sodium hydroxide (50% w/w solution) was added slowly until pH 7 and a pale yellow/green solid formed. The solid was isolated by filtration and air dried to provide 8.4 g of 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol. MS (APCI) m/z=246.0.

Part B

To a stirred solution (pale orange) of 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol (0.24 g, 1.0 mmol) was dissolved in anhydrous DMF (5 mL) was added cesium carbonate (3.0 eq., 1.0 g, 3.0 mmol) and 1.1 eq. of an 80% solution of propargyl bromide in toluene (0.16 g). The mixture was heated to 65° C. and maintained overnight. The reaction was quenched by slowly adding the reaction mixture to 10 volumes of water (50 mL). The resulting solid was collected by vacuum filtration, rinsed with acetonitrile and air dried, to provide 0.22 g of 2-ethyl-7-[(prop-2-ynyl)oxy]thiazolo[4,5-c]quinolin-4-amine as a pale-peach colored crystalline solid. MS (ACPI) m/z=284 (M+H)⁺.

Part C

To a stirred solution of 2-ethyl-7-[(prop-2-ynyl)oxy]thiazolo[4,5-c]quinolin-4-amine (0.18 g, 0.635 mmol), and triethylamine (3.0 eq. 0.27 ml, 1.9 mmol) dissolved in anhydrous DMF (5 mL) was added a solution of 3-iodopyridine (1.1 eq. 0.14 g, 0.699 mmol), copper iodide (0.04 eq., 4.8 mg, 0.025 mmol), and PdCl₂(PPh₃)₂(0.02 eq., 9.12 mg, 0.013 mmol) in anhydrous DMF (10 mL). The reaction mixture was heated to 65° C. under a nitrogen atmosphere for 24 hours. The reaction was quenched by slowly pouring it into water (100 ml). The mixture was extracted with dichloromethane (4×25 ml). The organic fractions were combined and concentrated to dryness. The resulting solid was recrystallized from acetonitrile to provide 0.19 g of 2-ethyl-7-{[(3-(pyridin-3-yl)prop-2-ynyl]oxy}thiazolo[4,5-c]quinolin-4-amine. MS (APCI) m/z=361.1 (M+H).

Part D

A glass Parr vessel was charged with a golden solution of 2-ethyl-7-{[(3-(pyridin-3-yl)prop-2-ynyl]oxy}thiazolo[4,5-c]quinolin-4-amine in 1:1 ethyl acetate:ethanol (150 mL), and 10% Pd/C catalyst (20 mg). The reaction vessel was evacuated and charged with hydrogen (˜50 psi, 3.4×10⁵Pa). The mixture was shaken for 10 hours at ambient temperature. At this time the reaction was analyzed by thin layer chromatography (10% methanol in dichloromethane) and found to be incomplete. The reaction vessel was re-charged with additional catalyst (23 mg) and hydrogen (˜50 psi, 3.4×10⁵Pa) and shaken an additional 48 hours. The reaction mixture was filtered to remove catalyst, and then concentrated to dryness. The desired product was purified by HPFC (eluting with a gradient of 0-20% CMA in chloroform, (1440 ml)), followed by recrystallization from acetonitrile, to provide 0.1 g of 2-ethyl-7-[3-(pyridin-3-yl)propoxy]thiazolo[4,5-c]quinolin-4-amine as off white crystals, mp 172-173° C. MS (APCI) m/z 365 (M+H)⁺.

Example 31
2-Propyl-7-[(thiazol-4-yl)methoxy]thiazolo[4,5-c]quinolin-4-amine

embedded image

A mixture of 4-amino-2-propylthiazolo[4,5-c]quinolin-7-ol acetate (318 mg, 1.0 mmol), cesium carbonate (1.3 g, 4.0 mmol), tetrabutylammonium bromide (322 mg, 1.0 mmol), and DMF (15 mL) was stirred at 75° C. for 10 minutes. 4-(Chloromethyl)thiazole hydrochloride (187 mg, 1.1 mmol) was added. Additional 4-(chloromethyl)thiazole hydrochloride (1 eq. total) was added in small portions over a period of 3 hours. The reaction mixture was poured into water (100 mL). A solid was isolated by filtration, allowed to dry, dissolved in dichloromethane, and then purified by HPFC eluting with a gradient of 0-25% CMA in chloroform over 1400 mL and then 25% CMA in chloroform over 600 mL. The resulting solid was recrystallized from acetonitrile to provide 200 mg of 2-propyl-7-[(thiazol-4-yl)methoxy]thiazolo[4,5-c]quinolin-4-amine as an off-white solid, mp 218.0-220.0° C. MS (APCI) m/z 357 (M+H)⁺; Anal. calcd for C₁₇H₁₆N₄OS₂.0.2H₂O: C, 56.71; H, 4.59; N, 15.56. Found C, 56.66; H, 4.29; N, 15.45.

Example 32
2-Propyl-7-[(pyridin-3-yl)methoxy]thiazolo[4,5-c]quinolin-4-amine

embedded image

A mixture of 4-amino-2-propylthiazolo[4,5-c]quinolin-7-ol acetate (318 mg, 1.0 mmol), cesium carbonate (1.3 g, 4.0 mmol), and DMF (20 mL) was stirred at 75° C. for 10 minutes. 3-(Iodomethyl)pyridine hydroiodide (381 mg, 1.1 mmol) was added in portions over a period of 3 hours. The heat source was removed and the reaction mixture was stirred at ambient temperature overnight. The reaction mixture was diluted with water (250 mL), stirred for 1 hour, and then filtered. The isolated solid was rinsed with water and then dried to provide a brown powder. This material was dissolved in dichloromethane and then purified by HPFC eluting with a gradient of 0-20% CMA in chloroform over 1400 mL and then 20% CMA in chloroform over 600 mL. The resulting solid was recrystallized from acetonitrile to provide 160 mg of 2-propyl-7-[(pyridin-3-yl)methoxy]thiazolo[4,5-c]quinolin-4-amine as an off-white solid, mp 167.0-169.0° C. MS (APCI) m/z 351 (M+H)⁺; Anal. calcd for C₁₉H₁₈N₄OS: C, 65.12; H, 5.18; N, 15.99. Found C, 65.25; H, 5.06; N, 16.03.

Example 33
2-Propyl-7-[2-(pyrrol-1-yl)ethoxy]thiazolo[4,5-c]quinolin-4-amine

embedded image

A mixture of 4-amino-2-propylthiazolo[4,5-c]quinolin-7-ol acetate (318 mg, 1.0 mmol), cesium carbonate (1.3 g, 4.0 mmol), and DMF (20 mL) was stirred at 75° C. for 10 minutes. 1-(2-Bromoethyl)pyrrole (200 mg, 1.1 mmol) was added dropwise over a period of 10 minutes. After 3 hours an additional equivalent of cesium carbonate was added in a single portion followed by the dropwise addition of an equivalent of 1-(2-bromoethyl)pyrrole. The reaction mixture was stirred overnight and then an additional equivalent of both cesium carbonate and 1-(2-bromoethyl)pyrrole were added. After 1 hour the heat source was removed; the reaction mixture was diluted with water (250 mL), stirred for 1 hour, and then filtered. The isolated solid was rinsed with water and then dried to provide a brown powder. This material was dissolved in dichloromethane and then purified by HPFC eluting with a gradient of 0-15% CMA in chloroform over 1500 mL. The resulting solid was recrystallized from acetonitrile to provide 143 mg of 2-propyl-7-[2-(pyrrol-1-yl)ethoxy]thiazolo[4,5-c]quinolin-4-amine as an off-white solid, mp 158.0-160.0° C. MS (ESI) m/z 353 (M+H)⁺; Anal. calcd for C₁₉H₂₀N₄OS: C, 64.75; H, 5.72; N, 15.90. Found C, 64.86; H, 5.38; N, 16.00.

Example 34
2-Propyl-7-[3-(pyrrol-1-yl)propoxy]thiazolo[4,5-c]quinolin-4-amine

embedded image

A mixture of 4-amino-2-propylthiazolo[4,5-c]quinolin-7-ol acetate (318 mg, 1.0 mmol), cesium carbonate (1.3 g, 4.0 mmol), and DMF (20 mL) was stirred at 75° C. for 10 minutes. 1-(2-Bromopropyl)pyrrole (206 mg, 1.1 mmol) was added dropwise over a period of 10 minutes. After 3 hours an additional equivalent of cesium carbonate was added in a single portion followed by the dropwise addition of an equivalent of 1-(2-bromopropyl)pyrrole. After 1 additional hour the heat source was removed; the reaction mixture was diluted with water (250 mL), stirred for 1 hour, and then filtered. The isolated solid was rinsed with water and then dried to provide a brown powder. This material was dissolved in dichloromethane and then purified by HPFC eluting with a gradient of 0-20% CMA in chloroform over 1500 mL. The resulting solid was recrystallized from acetonitrile to provide 168 mg of 2-propyl-7-[3-(pyrrol-1-yl)propoxy]thiazolo[4,5-c]quinolin-4-amine as an off-white solid, mp 152.0-154.0° C. MS (ESI) m/z 367 (M+H)⁺; Anal. calcd for C₂₀H₂₂N₄OS: C, 65.55; H, 6.05; N, 15.29. Found C, 65.52; H, 5.80; N, 15.37.

Example 35
7-[(3,5-Dimethylisoxazol-4-yl)methoxy]-2-propylthiazolo[4,5-c]quinolin-4-amine

embedded image

A mixture of 4-amino-2-propylthiazolo[4,5-c]quinolin-7-ol acetate (318 mg, 1.0 mmol), cesium carbonate (1.3 g, 4.0 mmol), and DMF (20 mL) was stirred at 75° C. for 10 minutes. 4-(Chloromethyl)-3,5-dimethylisoxazole (160 mg, 1.1 mmol) was added dropwise over a period of 10 minutes. After 3 hours an additional equivalent of cesium carbonate was added in a single portion followed by the dropwise addition of an equivalent of 4-(chloromethyl)-3,5-dimethylisoxazole. After 1 additional hour the heat source was removed; the reaction mixture was diluted with water (250 mL), stirred for 1 hour, and then filtered. The isolated solid was rinsed with water and then dried to provide a brown powder. This material was dissolved in dichloromethane and then purified by HPFC eluting with a gradient of 0-5% methanol in dichloromethane for over 1000 mL and then with 5% methanol in dichloromethane over 400 mL. The resulting solid was recrystallized from acetonitrile to provide 156 mg of 7-[(3,5-dimethylisoxazol-4-yl)methoxy]-2-propylthiazolo[4,5-c]quinolin-4-amine as an off-white solid, mp 178.0-180.0° C. MS (ESI) m/z 369 (M+H)⁺; Anal. calcd for C₁₉H₂₀N₄O₂S: C, 61.94; H, 5.47; N, 15.21. Found C, 61.98; H, 5.25; N, 15.26.

Example 36
2-Ethyl-7-{[5-(trifluoromethyl)furan-2-yl]methoxy}thiazolo[4,5-c]quinolin-4-amine

embedded image

A mixture of 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol (245 mg, 1.0 mmol), cesium carbonate (1.3 g, 4.0 mmol), and DMF (20 mL) was stirred at 75° C. for 10 minutes. 2-(Bromomethyl)-5-(trifluoromethyl)furan (252 mg, 1.1 mmol) was added in portions over a period of 30 minutes. The reaction mixture was stirred for 1 hour and then the heat source was removed. The reaction mixture was diluted with water (250 mL), stirred for 1 hour, and then filtered. The isolated solid was rinsed with water and then dried to provide a brown powder. This material was dissolved in dichloromethane and then purified by HPFC eluting with a gradient of 0-15 CMA in chloroform 700 mL and then with 15% CMA in chloroform over 200 mL. The resulting solid was recrystallized from acetonitrile to provide 125 mg of 2-ethyl-7-{[5-(trifluoromethyl)furan-2-yl]methoxy}thiazolo[4,5-c]quinolin-4-amine as an off-white solid, mp 152-154° C. MS (ESI) m/z 394 (M+H)⁺; Anal. calcd for C₁₈H₁₄F₃N₃O₂S: C, 54.96; H, 3.59; N, 10.68. Found: C, 54.90; H, 3.46; N, 10.52.

Example 37
4-{[(4-Amino-2-ethylthiazolo[4,5-c]quinolin-7-yl)oxy]methyl}-N-[2-(1H-indol-2-yl)ethyl]benzenesulfonamide

embedded image

A mixture of 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol (245 mg, 1.0 mmol), cesium carbonate (1.3 g, 4.0 mmol), and DMF (20 mL) was stirred at 75° C. for 10 minutes. {[4-(Bromomethyl)phenyl]sulfonyl}[2-(indol-3-yl)ethyl]amine (432 mg, 1.1 mmol) was added in portions over a period of 30 minutes. Several small additions of {[4-(bromomethyl)phenyl]sulfonyl}[2-(indol-3-yl)ethyl]amine were made over several hours. The reaction mixture was diluted with water (250 mL) and then extracted with chloroform (3×100 mL). The extracts were combined and concentrated under reduced pressure. The residue was purified by HPFC eluting with a gradient of 0-20% CMA in chloroform over 700 mL and then with 20% CMA in chloroform over 400 mL. The resulting solid was recrystallized from 100:1 acetonitrile:water to provide 6 mg of 4-{[(4-amino-2-ethylthiazolo[4,5-c]quinolin-7-yl)oxy]methyl}-N-[2-(1H-indol-2-yl)ethyl]benzenesulfonamide as an off-white solid, mp 100.0-101.0° C. MS (APCI) m/z 558 (M+H)⁺; Anal. calcd for C₂₉H₂₇N₅O₃S₂: C, 62.46; H, 4.88; N, 12.56. Found C, 62.27; H, 4.63; N, 12.73.

Example 38
7-[(6-Chloropyridin-2-yl)methoxy]-2-ethylthiazolo[4,5-c]quinolin-4-amine

embedded image

A mixture of 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol (245 mg, 1.0 mmol), cesium carbonate (1.3 g, 4.0 mmol), tetrabutylammonium bromide (322 mg, 1.0 mmol), and DMF (15 mL) was stirred at 75° C. for 10 minutes. 2-Chloro-5-(chloromethyl)pyridine (178 mg, 1.1 mmol) was added in portions over a period of 30 minutes. The reaction mixture was stirred for 1 hour and then the heat source was removed. The reaction mixture was diluted with water (200 mL) and then filtered. The isolated solid was rinsed with water and then dried to provide an off white powder. This material was dissolved in dichloromethane and then purified by HPFC eluting with a gradient of 0-15 CMA in chloroform 700 mL and then with 15% CMA in chloroform over 600 mL. The resulting solid was slurried with hot 10:1 acetonitrile:methanol to provide 216 mg of 7-[(6-chloropyridin-2-yl)methoxy]-2-ethylthiazolo[4,5-c]quinolin-4-amine as a pale yellow solid, mp 229.0-230.0° C. MS (APCI) m/z 371 (M+H)⁺; Anal. calcd for C₁₈H₁₅ClN₄OS.0.1CHCl₃: C, 57.06; H, 4.32; N, 14.63. Found C, 56.79; H, 3.98; N, 14.63.

Example 39
7-[2-(3,5-Dimethyl-1H-pyrazol-4-yl)ethoxy]-2-ethylthiazolo[4,5-c]quinolin-4-amine

embedded image

A mixture of 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol (245 mg, 1.0 mmol), cesium carbonate (1.3 g, 4.0 mmol), and DMF (20 mL) was stirred at 75° C. for 10 minutes. 4-(Bromoethyl)-3,5-dimethyl-1H-pyrazole (223 mg, 1.1 mmol) was added in portions over a period of 30 minutes. The reaction mixture was stirred for 20 minutes and then the heat source was removed. The reaction mixture was diluted with water (250 mL), stirred overnight, and then filtered. The isolated solid was rinsed with water and then dried to provide a tan powder. This material was dissolved in dichloromethane and then purified by HPFC eluting with a gradient of 0-30% CMA in chloroform 700 mL and then with 30% CMA in chloroform over 200 mL. The resulting solid was recrystallized from 50:1 acetonitrile:methanol (40 mL) to provide 205 mg of 7-[2-(3,5-dimethyl-1H-pyrazol-4-yl)ethoxy]-2-ethylthiazolo[4,5-c]quinolin-4-amine as an off white solid, mp 195.0-197.0° C. MS (APCI) m/z 368 (M+H)⁺; Anal. calcd for C₁₉H₂₁N₅OS: C, 62.10; H, 5.764; N, 19.06. Found C, 61.95; H, 5.53; N, 19.09.

Example 40
(1-{[3-(4-Amino-2-ethylthiazolo[4,5-c]quinolin-7-yl)oxy]propyl}-1H-[1,2,3]triazol-4-yl)methanol

embedded image

Part A

A mixture of 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol (1.00 mg, 4.08 mmol), cesium carbonate (5.30 g, 16.3 mmol), and DMF (40 mL) was stirred at 50° C. for 10 minutes. A portion (0.05 mL) of a solution (1.1 mL) of 1-bromo-3-chloropropane (705 mg, 4.48 mmol) in DMF was added every 7 minutes. After 2 hours the reaction mixture was poured into water (225 mL). The mixture was stirred for 30 minutes and then filtered. The isolated solid was dried to provide 785 mg of 7-(3-chloropropoxy)-2-ethylthiazolo[4,5-c]quinolin-4-amine as a brown solid.

Part B

A solution of 7-(3-chloropropoxy)-2-ethylthiazolo[4,5-c]quinolin-4-amine (684 mg, 2.12 mmol) in DMF (20 mL) was heated to 110° C. Sodium azide (151 mg, 2.33 mol) was added in a single portion. After 1 hour the reaction mixture was poured into water (100 mL). The mixture was extracted with chloroform (3×100 mL). The combined extracts were concentrated under reduced pressure. The residue was dissolved in chloroform and purified by HPFC eluting with a gradient of 0-20% CMA in chloroform over 700 mL and then with 20% CMA in chloroform over 600 mL to provide 400 mg of 7-(3-azidopropxy)-2-ethylthiazolo[4,5-c]quinolin-4-amine as a pale yellow solid.

Part C

The material from Part B (1.21 mmol), propargyl alcohol (134 mg, 2.4 mmol), copper(II) sulfate pentahydrate (30 mg, 0.12 mmol), sodium ascorbate (24 mg, 0.12 mmol), water (2 mL), and DMF (8 mL) were combined and stirred at 70° C. for 2 hours. The reaction mixture was cooled, diluted with water (200 mL), stirred for 40 minutes, and then filtered. The isolated solid was dissolved in chloroform and purified by HPFC eluting with a gradient of 0-30% CMA in chloroform over 700 mL and then with 30% CMA in chloroform over 600 mL. The resulting solid was slurried with hot 10:1 acetonitrile:methanol to provide 280 mg of (1-{[3-(4-amino-2-ethylthiazolo[4,5-c]quinolin-7-yl)oxy]propyl}-1H-[1,2,3]triazol-4-yl)methanol as an off white solid, mp 194.0-197.0° C. MS (APCI) m/z 385 (M+H)⁺; Anal. calcd for C₁₈H₂₀N₆O₂S: C, 56.23; H, 5.24; N, 21.86. Found C, 56.49; H, 5.12; N, 21.94.

Example 41
7-[(1,3-Benzothiazol-2-yl)methoxy]-2-ethylthiazolo[4,5-c]quinolin-4-amine

embedded image

A scintillation vial was charged with 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol and anhydrous N,N-dimethylformamide (DMF, 2 mL). The mixture was warmed until a solution was obtained. An additional amount of DMF (1 mL) was added. To this stirred orange solution was added cesium carbonate (3.0 eq.) and a solution of 2-(bromomethyl)benzothiazole dissolved in DMF (2 mL). Additional DMF (1 mL) was used to rinse the vial. The vial was capped and heated to 60° C. overnight. The reaction was monitored by HPLC. The reaction was quenched by adding the reaction mixture dropwise to water (60 mL) with stirring. A precipitate formed. The solid was collected by vacuum filtration. The solid was then dissolved in methanol and adsorbed onto silica gel (6 g) for purification by HPFC (0-15% CMA in chloroform, 1440 mL). Pure fractions were combined and concentrated; the resulting solid was recrystallized from acetonitrile to provide 7-[(1,3-benzothiazol-2-yl)methoxy]-2-ethylthiazolo[4,5-c]quinolin-4-amine as a white crystalline solid, mp. 211-212° C. MS (APCI) m/z 393 (M+H)⁺. Anal. calcd C₂₀H₁₆N₄OS₂.0.6H₂O: C, 59.56; H, 4.30; N, 13.89. Found: C, 59.66; H, 4.08; N, 13.80.

Example 42
Methyl 5-{[(4-amino-2-ethylthiazolo[4,5-c]quinolin-7-yl)oxy]methyl}-2-furoate

embedded image

A scintillation vial was charged with 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol (1.0 eq., 1.0 mmol) and anhydrous DMF (2 mL). The mixture was warmed until a solution was obtained. An additional amount of DMF (1 mL) was added. To this stirred orange solution was added cesium carbonate (3.0 eq., 3.0 mmol) and a solution of ethyl 5-(chloromethyl)-2-furancarboxylate (1.0 eq., 1.0 mmol) dissolved in DMF (2 mL). Additional DMF (1 mL) was used to rinse the vial. The vial was capped and heated to 60° C. overnight. The reaction was monitored by HPLC. The reaction was quenched by adding the reaction mixture drop-wise to water (60 mL) with stirring. A precipitate formed. Crude ethyl 5-{[(4-amino-2-ethylthiazolo[4,5-c]quinolin-7-yl)oxy]methyl}-2-furoate was isolated as a solid by vacuum filtration. The solid was then dissolved in methanol and adsorbed onto silica gel (6 g) for purification by HPFC (0-15% CMA in chloroform, 1440 mL). Pure fractions were combined and concentrated to provide a solid which analysis indicated was the methyl ester. This material was recrystallized from acetonitrile to provide methyl 5-{[(4-amino-2-ethylthiazolo[4,5-c]quinolin-7-yl)oxy]methyl}-2-furoate as a light yellow crystalline solid, mp 184-186° C. MS (APCI) m/z 384 (M+H)⁺. Anal. calcd for C₁₉H₁₇N₃O₄S.0.30CH₃CN: C, 59.49; H, 4.56; N, 11.68. Found: C, 59.35; H, 4.22; N, 11.71.

Example 43
6-{[(4-Amino-2-ethylthiazolo[4,5-c]quinolin-7-yl)oxy]methyl}pyridin-2-yl)methanol

embedded image

A scintillation vial was charged with 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol (1.0 eq., 1.0 mmol) and anhydrous DMF (2 mL). The mixture was warmed until a solution was obtained. An additional amount of DMF (1 mL) was added. To this stirred orange solution was added cesium carbonate (3.0 eq., 3.0 mmol) and a solution of 6-(bromomethyl)-2-pyridinemethanol (1.0 eq., 1.0 mmol) dissolved in DMF (2 mL). Additional DMF (1 mL) was used to rinse the vial. The vial was capped and heated to 60° C. overnight. The reaction was monitored by HPLC. The reaction was quenched by adding the reaction mixture drop-wise to water (60 mL) with stirring. A precipitate formed. The solid was collected by vacuum filtration. The solid was then dissolved in methanol and adsorbed onto silica gel (6 g) for purification by HPFC (0-15% CMA-chloroform, 1440 mL). Pure fractions were combined and concentrated; the resulting solid was recrystallized from acetonitrile to provide 6-{[(4-amino-2-ethylthiazolo[4,5-c]quinolin-7-yl)oxy]methyl}pyridin-2-yl)methanol as a pale yellow crystalline solid, mp 186-187° C. MS (APCI) m/z 367 (M+H)⁺. Anal. calcd for C₁₉H₁₈N₄O₂S.0.30H₂O: C, 61.37; H, 5.04; N, 15.07. Found: C, 61.08; H, 4.92; N, 15.11.

Example 44
Methyl 6-[(4-amino-2-ethylthiazolo[4,5-c]quinolin-7-yl)oxy]nicotinate

embedded image

A round bottom flask was charged with 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol (1.0 eq., 2.0 mmol), methyl 6-chloronicotinate (1.0 eq., 2.0 mmol), cesium carbonate (3.0 eq. 6.0 mmol), and anhydrous 1,4-dioxane (45 mL). The mixture was heated to reflux for 24 hours. The reaction was monitored by HPLC. The reaction mixture was concentrated to dryness. The resulting solid was then dissolved in methanol and adsorbed onto silica gel (6 g) for purification by HPFC (0-15% CMA in chloroform, 1440 mL). Pure fractions were combined and concentrated; the resulting solid was recrystallized from acetonitrile to provide methyl 6-[(4-amino-2-ethyl[1,3]thiazolo[4,5-c]quinolin-7-yl)oxy]nicotinate as a light peach colored crystalline solid, mp 213-214° C. MS (APCI) m/z 381 (M+H)⁺. Anal. calcd for C₁₉H₁₆N₄O₃S: C, 59.99; H, 4.24; N, 14.73. Found: C, 59.76; H, 4.19; N, 14.71.

Example 45
2-ethyl-7-[2-(1H-indol-3-yl)ethoxy]thiazolo[4,5-c]quinolin-4-amine

embedded image

A scintillation vial was charged with 4-amino-2-ethylthiazolo[4,5-c]quinolin-7-ol (1.0 eq., 1.0 mmol) and anhydrous DMF (2 mL). The mixture was warmed until a solution was obtained. An additional amount of DMF (1 mL) was added. To this stirred orange solution was added cesium carbonate (3.0 eq., 3.0 mmol) and a solution of 3-(2-bromoethyl)indole (1.0 eq., 1.0 mmol) dissolved in DMF (2 mL). Additional DMF (1 mL) was used to rinse the vial. The vial was capped and heated to 60° C. overnight. The reaction was monitored by HPLC. The reaction was quenched by adding the reaction mixture drop-wise to water (60 ml) with stirring. A precipitate formed. The solid was collected by vacuum filtration. The solid was then dissolved in methanol and adsorbed onto silica gel (6 g) for purification by HPFC (0-15% CMA in chloroform, 1440 mL). Pure fractions were combined and concentrated; the resulting solid was recrystallized from methanol to provide a peach colored crystalline solid, mp 218-220° C. MS (APCI) m/z 389 (M+H)⁺. Anal. calcd for C₂₂H₂₀N₄OS.0.8 CH₃OH: C, 66.13; H, 5.65; N, 13.53. Found: C, 66.43; H, 5.03; N, 13.90.

Exemplary Compounds

Certain exemplary compounds, including some of those described above in the Examples, have the following Formulas (IIa or IIIa) and the following R₂and R_3asubstituents, wherein each line of the table is matched with Formula IIa or IIIa to represent a specific compound.

embedded image

R₂
R₃

methyl
4-fluorobenzyloxy

methyl
2,4-difluorobenzyloxy

methyl
6-chlorobenzyloxy

methyl
2-chlorobenzyloxy

methyl
(pyridin-3-yl)methoxy

methyl
(pyridin-4-yl)methoxy

methyl
2-(4-fluorophenyl)ethoxy

ethyl
4-fluorobenzyloxy

ethyl
2,4-difluorobenzyloxy

ethyl
6-chlorobenzyloxy

ethyl
2-chlorobenzyloxy

ethyl
(pyridin-3-yl)methoxy

ethyl
(pyridin-4-yl)methoxy

ethyl
2-(4-fluorophenyl)ethoxy

propyl
4-fluorobenzyloxy

propyl
2,4-difluorobenzyloxy

propyl
6-chlorobenzyloxy

propyl
2-chlorobenzyloxy

propyl
(pyridin-3-yl)methoxy

propyl
(pyridin-4-yl)methoxy

propyl
2-(4-fluorophenyl)ethoxy

methoxymethyl
4-fluorobenzyloxy

methoxymethyl
2,4-difluorobenzyloxy

methoxymethyl
6-chlorobenzyloxy

methoxymethyl
2-chlorobenzyloxy

methoxymethyl
(pyridin-3-yl)methoxy

methoxymethyl
(pyridin-4-yl)methoxy

methoxymethyl
2-(4-fluorophenyl)ethoxy

ethoxymethyl
4-fluorobenzyloxy

ethoxymethyl
2,4-difluorobenzyloxy

ethoxymethyl
6-chlorobenzyloxy

ethoxymethyl
2-chlorobenzyloxy

ethoxymethyl
(pyridin-3-yl)methoxy

ethoxymethyl
(pyridin-4-yl)methoxy

ethoxymethyl
2-(4-fluorophenyl)ethoxy

2-methoxyethyl
4-fluorobenzyloxy

2-methoxyethyl
2,4-difluorobenzyloxy

2-methoxyethyl
6-chlorobenzyloxy

2-methoxyethyl
2-chlorobenzyloxy

2-methoxyethyl
(pyridin-3-yl)methoxy

2-methoxyethyl
(pyridin-4-yl)methoxy

2-methoxyethyl
2-(4-fluorophenyl)ethoxy

Cytokine Induction in Human Cells

Compounds of the invention have been found to modulate cytokine biosynthesis by inducing the production of interferon α and/or tumor necrosis factor α in human cells when tested using the method described below.

An in vitro human blood cell system is used to assess cytokine induction. Activity is based on the measurement of interferon (α) and tumor necrosis factor (α) (IFN-α and TNF-α, respectively) secreted into culture media as described by Testerman et. al. in “Cytokine Induction by the Immunomodulators Imiquimod and S-27609”, Journal of Leukocyte Biology, 58, 365-372 (September, 1995).

Blood Cell Preparation for Culture

Whole blood from healthy human donors is collected by venipuncture into vacutainer tubes or syringes containing EDTA. Peripheral blood mononuclear cells (PBMC) are separated from whole blood by density gradient centrifugation using HISTOPAQUE-1077 (Sigma, St. Louis, Mo.) or Ficoll-Paque Plus (Amersham Biosciences Piscataway, N.J.). Blood is diluted 1:1 with Dulbecco's Phosphate Buffered Saline (DPBS) or Hank's Balanced Salts Solution (HBSS). Alternately, whole blood is placed in Accuspin (Sigma) or LeucoSep (Greiner Bio-One, Inc., Longwood, Fla.) centrifuge frit tubes containing density gradient medium. The PBMC layer is collected and washed twice with DPBS or HBSS and re-suspended at 4×10⁶cells/mL in RPMI complete. The PBMC suspension is added to 96 well flat bottom sterile tissue culture plates containing an equal volume of RPMI complete media containing test compound.

Compound Preparation

The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells. The compounds are generally tested at concentrations ranging from 30-0.014 μM. Controls include cell samples with media only, cell samples with DMSO only (no compound), and cell samples with reference compound.

Incubation

The solution of test compound is added at 60 μM to the first well containing RPMI complete and serial 3 fold dilutions are made in the wells. The PBMC suspension is then added to the wells in an equal volume, bringing the test compound concentrations to the desired range (usually 30-0.014 μM). The final concentration of PBMC suspension is 2×10⁶cells/mL. The plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37° C. in a 5% carbon dioxide atmosphere.

Separation

Following incubation the plates are centrifuged for 10 minutes at 1000 rpm (approximately 200×g) at 4° C. The cell-free culture supernatant is removed and transferred to sterile polypropylene tubes. Samples are maintained at −30 to −70° C. until analysis. The samples are analyzed for IFN-α by ELISA and for TNF-α by IGEN/BioVeris Assay.

Interferon (α) and Tumor Necrosis Factor (α) Analysis

IFN-α concentration is determined with a human multi-subtype colorimetric sandwich ELISA (Catalog Number 41105) from PBL Biomedical Laboratories, Piscataway, N.J. Results are expressed in pg/mL.

The TNF-α concentration is determined by ORIGEN M-Series Immunoassay and read on an IGEN M-8 analyzer from BioVeris Corporation, formerly known as IGEN International, Gaithersburg, Md. The immunoassay uses a human TNF-α capture and detection antibody pair (Catalog Numbers AHC3419 and AHC3712) from Biosource International, Camarillo, Calif. Results are expressed in pg/mL.

Assay Data and Analysis

In total, the data output of the assay consists of concentration values of TNF-α and IFN-α (y-axis) as a function of compound concentration (x-axis).

Analysis of the data has two steps. First, the greater of the mean DMSO (DMSO control wells) or the experimental background (usually 20 pg/mL for IFN-α and 40 pg/mL for TNF-α) is subtracted from each reading. If any negative values result from background subtraction, the reading is reported as “*”, and is noted as not reliably detectable. In subsequent calculations and statistics, “*”, is treated as a zero. Second, all background subtracted values are multiplied by a single adjustment ratio to decrease experiment to experiment variability. The adjustment ratio is the area of the reference compound in the new experiment divided by the expected area of the reference compound based on the past 61 experiments (unadjusted readings). This results in the scaling of the reading (y-axis) for the new data without changing the shape of the dose-response curve. The reference compound used is 2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-α,α-dimethyl-1H-imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No. 5,352,784; Example 91) and the expected area is the sum of the median dose values from the past 61 experiments.

The minimum effective concentration is calculated based on the background-subtracted, reference-adjusted results for a given experiment and compound. The minimum effective concentration (μmolar) is the lowest of the tested compound concentrations that induces a response over a fixed cytokine concentration for the tested cytokine (usually 20 pg/mL for IFN-α and 40 pg/mL for TNF-α). The maximal response is the maximal amount of cytokine (pg/ml) produced in the dose-response.

Cytokine Induction in Human Cells
High Throughput Screen

The CYTOKINE INDUCTION 1N HUMAN CELLS test method described above was modified as follows for high throughput screening.

Blood Cell Preparation for Culture

Whole blood from healthy human donors is collected by venipuncture into vacutainer tubes or syringes containing EDTA. Peripheral blood mononuclear cells (PBMC) are separated from whole blood by density gradient centrifugation using HISTOPAQUE-1077 (Sigma, St. Louis, Mo.) or Ficoll-Paque Plus (Amersham Biosciences Piscataway, N.J.). Whole blood is placed in Accuspin (Sigma) or LeucoSep (Greiner Bio-One, Inc., Longwood, Fla.) centrifuge frit tubes containing density gradient medium. The PBMC layer is collected and washed twice with DPBS or HBSS and re-suspended at 4×10⁶cells/mL in RPMI complete (2-fold the final cell density). The PBMC suspension is added to 96-well flat bottom sterile tissue culture plates.

Compound Preparation

The compounds are solubilized in dimethyl sulfoxide (DMSO). The compounds are generally tested at concentrations ranging from 30-0.014 μM. Controls include cell samples with media only, cell samples with DMSO only (no compound), and cell samples with a reference compound 2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-α,α-dimethyl-1H-imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No. 5,352,784; Example 91) on each plate. The solution of test compound is added at 7.5 mM to the first well of a dosing plate and serial 3 fold dilutions are made for the 7 subsequent concentrations in DMSO. RPMI Complete media is then added to the test compound dilutions in order to reach a final compound concentration of 2-fold higher (60-0.028 μM) than the final tested concentration range.

Incubation

Compound solution is then added to the wells containing the PBMC suspension bringing the test compound concentrations to the desired range (usually 30-0.014 μM) and the DMSO concentration to 0.4%. The final concentration of PBMC suspension is 2×10⁶cells/mL. The plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37° C. in a 5% carbon dioxide atmosphere.

Separation

Following incubation the plates are centrifuged for 10 minutes at 1000 rpm (approximately 200 g) at 4° C. 4-plex Human Panel MSD MULTI-SPOT 96-well plates are pre-coated with the appropriate capture antibodies by MesoScale Discovery, Inc. (MSD, Gaithersburg, Md.). The cell-free culture supernatants are removed and transferred to the MSD plates. Fresh samples are typically tested, although they may be maintained at −30 to −70° C. until analysis.

Interferon-α and Tumor Necrosis Factor-α Analysis

MSD MULTI-SPOT plates contain within each well capture antibodies for human TNF-α and human IFN-α that have been pre-coated on specific spots. Each well contains four spots: one human TNF-α capture antibody (MSD) spot, one human IFN-α capture antibody (PBL Biomedical Laboratories, Piscataway, N.J.) spot, and two inactive bovine serum albumin spots. The human TNF-α capture and detection antibody pair is from MesoScale Discovery. The human IFN-α multi-subtype antibody (PBL Biomedical Laboratories) captures all IFN-α subtypes except IFN-αF (IFNA21). Standards consist of recombinant human TNF-α (R&D Systems, Minneapolis, Minn.) and IFN-α (PBL Biomedical Laboratories). Samples and separate standards are added at the time of analysis to each MSD plate. Two human IFN-α detection antibodies (Cat. Nos. 21112 & 21100, PBL) are used in a two to one ratio (weight:weight) to each other to determine the IFN-α concentrations. The cytokine-specific detection antibodies are labeled with the SULFO-TAG reagent (MSD). After adding the SULFO-TAG labeled detection antibodies to the wells, each well's electrochemoluminescent levels are read using MSD's SECTOR HTS READER. Results are expressed in pg/mL upon calculation with known cytokine standards.

Assay Data and Analysis

In total, the data output of the assay consists of concentration values of TNF-α or IFN-α (y-axis) as a function of compound concentration (x-axis).

A plate-wise scaling is performed within a given experiment aimed at reducing plate-to-plate variability associated within the same experiment. First, the greater of the median DMSO (DMSO control wells) or the experimental background (usually 20 pg/mL for IFN-α and 40 pg/mL for TNF-α) is subtracted from each reading. Negative values that may result from background subtraction are set to zero. Each plate within a given experiment has a reference compound that serves as a control. This control is used to calculate a median expected area under the curve across all plates in the assay. A plate-wise scaling factor is calculated for each plate as a ratio of the area of the reference compound on the particular plate to the median expected area for the entire experiment. The data from each plate are then multiplied by the plate-wise scaling factor for all plates. Only data from plates bearing a scaling factor of between 0.5 and 2.0 (for both cytokines IFN-α, TNF-α) are reported. Data from plates with scaling factors outside the above mentioned interval are retested until they bear scaling factors inside the above mentioned interval. The above method produces a scaling of the y-values without altering the shape of the curve. The reference compound used is 2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-α,α-dimethyl-1H-imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No. 5,352,784; Example 91). The median expected area is the median area across all plates that are part of a given experiment.

A second scaling may also be performed to reduce inter-experiment variability (across multiple experiments). All background-subtracted values are multiplied by a single adjustment ratio to decrease experiment-to-experiment variability. The adjustment ratio is the area of the reference compound in the new experiment divided by the expected area of the reference compound based on an average of previous experiments (unadjusted readings). This results in the scaling of the reading (y-axis) for the new data without changing the shape of the dose-response curve. The reference compound used is 2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-α,α-dimethyl-1H-imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No. 5,352,784; Example 91) and the expected area is the sum of the median dose values from an average of previous experiments.

TNF-α Inhibition in Mouse Cells

Certain compounds of the invention may modulate cytokine biosynthesis by inhibiting production of tumor necrosis factor α (TNF-α) when tested using the method described below.

The mouse macrophage cell line Raw 264.7 is used to assess the ability of compounds to inhibit tumor necrosis factor-α (TNF-α) production upon stimulation by lipopolysaccharide (LPS).

Single Concentration Assay:

Blood Cell Preparation for Culture

Raw cells (ATCC) are harvested by gentle scraping and then counted. The cell suspension is brought to 3×10⁵cells/mL in RPMI with 10% fetal bovine serum (FBS). Cell suspension (100 μL) is added to 96-well flat bottom sterile tissues culture plates (Becton Dickinson Labware, Lincoln Park, N.J.). The final concentration of cells is 3×10⁴cells/well. The plates are incubated for 3 hours. Prior to the addition of test compound the medium is replaced with colorless RPMI medium with 3% FBS.

Compound Preparation

The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells. Compounds are tested at 5 μM. LPS (Lipopolysaccaride from Salmonella typhimurium, Sigma-Aldrich) is diluted with colorless RPMI to the EC₇₀concentration as measured by a dose response assay.

Incubation

A solution of test compound (1 μl) is added to each well. The plates are mixed on a microtiter plate shaker for 1 minute and then placed in an incubator. Twenty minutes later the solution of LPS (1 μL, EC₇₀concentration ˜10 ng/ml) is added and the plates are mixed for 1 minute on a shaker. The plates are incubated for 18 to 24 hours at 37° C. in a 5% carbon dioxide atmosphere.

TNF-α Analysis

Following the incubation the supernatant is removed with a pipet. TNF-α concentration is determined by ELISA using a mouse TNF-α kit (from Biosource International, Camarillo, Calif.). Results are expressed in pg/mL. TNF-α expression upon LPS stimulation alone is considered a 100% response.

Dose Response Assay:

Blood Cell Preparation for Culture

Raw cells (ATCC) are harvested by gentle scraping and then counted. The cell suspension is brought to 4×10⁵cells/mL in RPMI with 10% FBS. Cell suspension (250 μL) is added to 48-well flat bottom sterile tissues culture plates (Costar, Cambridge, Mass.). The final concentration of cells is 1×10⁵cells/well. The plates are incubated for 3 hours. Prior to the addition of test compound the medium is replaced with colorless RPMI medium with 3% FBS.

Compound Preparation

The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells. Compounds are tested at 0.03, 0.1, 0.3, 1, 3, 5 and 10 μM. LPS (Lipopolysaccaride from Salmonella typhimurium, Sigma-Aldrich) is diluted with colorless RPMI to the EC₇₀concentration as measured by dose response assay.

Incubation

A solution of test compound (200 μl) is added to each well. The plates are mixed on a microtiter plate shaker for 1 minute and then placed in an incubator. Twenty minutes later the solution of LPS (200 μL, EC₇₀concentration ˜10 ng/ml) is added and the plates are mixed for 1 minute on a shaker. The plates are incubated for 18 to 24 hours at 37° C. in a 5% carbon dioxide atmosphere.

TNF-α Analysis

The complete disclosures of the patents, patent documents, and publications cited herein are incorporated by reference in their entirety as if each were individually incorporated. Various modifications and alterations to this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention. It should be understood that this invention is not intended to be unduly limited by the illustrative embodiments and examples set forth herein and that such examples and embodiments are presented by way of example only with the scope of the invention intended to be limited only by the claims set forth herein as follows.

Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

CPC

US Classifications

Field of Search

US

International Classifications

Term Extension

Abstract

Description

Claims

RELATED APPLICATIONS

PCT Information

US Referenced Citations (366)

Foreign Referenced Citations (212)

Related Publications (1)

Provisional Applications (1)

Number	Name	Date	Kind
3314941	Littell et al.	Apr 1967	A
3450693	Suzuki et al.	Jun 1969	A
3670086	Pryor et al.	Jun 1972	A
3692907	Fleming et al.	Sep 1972	A
3891660	Denzel et al.	Jun 1975	A
3899508	Wikel	Aug 1975	A
3917624	Abu El-Haj et al.	Nov 1975	A
4006237	Buckle et al.	Feb 1977	A
4053588	Konig et al.	Oct 1977	A
4381344	Rideout et al.	Apr 1983	A
4552874	Mardin et al.	Nov 1985	A
4563525	Campbell, Jr.	Jan 1986	A
4593821	Brule	Jun 1986	A
4668686	Meanwell et al.	May 1987	A
4689338	Gerster	Aug 1987	A
4690930	Takada et al.	Sep 1987	A
4698346	Musser et al.	Oct 1987	A
4698348	Gerster	Oct 1987	A
4753951	Takada et al.	Jun 1988	A
4758574	Robertson et al.	Jul 1988	A
4774339	Haugland et al.	Sep 1988	A
4775674	Meanwell et al.	Oct 1988	A
4800206	Alig et al.	Jan 1989	A
4826830	Han et al.	May 1989	A
4837378	Borgman	Jun 1989	A
4880779	Gallaher	Nov 1989	A
4904669	Knoll et al.	Feb 1990	A
4929624	Gerster et al.	May 1990	A
4988714	Alig et al.	Jan 1991	A
4988815	Andre et al.	Jan 1991	A
5037986	Gerster	Aug 1991	A
5175296	Gerster	Dec 1992	A
5187288	Kang et al.	Feb 1993	A
5225183	Purewal et al.	Jul 1993	A
5238944	Wick et al.	Aug 1993	A
5248782	Haugland et al.	Sep 1993	A
5266575	Gerster	Nov 1993	A
5268376	Gerster	Dec 1993	A
5274113	Kang et al.	Dec 1993	A
5342784	Yamada et al.	Aug 1994	A
5346905	Gerster	Sep 1994	A
5352680	Portoghese et al.	Oct 1994	A
5352784	Nikolaides et al.	Oct 1994	A
5367076	Gerster	Nov 1994	A
5376501	Marien et al.	Dec 1994	A
5378848	Takada et al.	Jan 1995	A
5389640	Gerster et al.	Feb 1995	A
5395937	Nikolaides et al.	Mar 1995	A
5444065	Nikolaides et al.	Aug 1995	A
5446153	Lindstrom et al.	Aug 1995	A
5446160	Stucky et al.	Aug 1995	A
5482936	Lindstrom	Jan 1996	A
5494916	Lindstrom et al.	Feb 1996	A
5500228	Lawter et al.	Mar 1996	A
5525612	Gerster	Jun 1996	A
5530114	Bennett et al.	Jun 1996	A
5569450	Duan et al.	Oct 1996	A
5571819	Sabb et al.	Nov 1996	A
5578727	Andre et al.	Nov 1996	A
5585612	Harp, Jr.	Dec 1996	A
5602256	Andr e et al.	Feb 1997	A
5605899	Gerster et al.	Feb 1997	A
5612377	Crooks et al.	Mar 1997	A
5627281	Nikolaides et al.	May 1997	A
5644063	Lindstrom et al.	Jul 1997	A
5648516	Nikolaides et al.	Jul 1997	A
5693811	Lindstrom	Dec 1997	A
5714608	Gerster	Feb 1998	A
5731193	Mori et al.	Mar 1998	A
5736553	Wick et al.	Apr 1998	A
5741908	Gerster et al.	Apr 1998	A
5741909	Gerster et al.	Apr 1998	A
5750134	Scholz et al.	May 1998	A
5756747	Gerster et al.	May 1998	A
5776432	Schultz et al.	Jul 1998	A
5780045	McQuinn et al.	Jul 1998	A
5837809	Grandy et al.	Nov 1998	A
5840744	Borgman	Nov 1998	A
5854257	Armitage et al.	Dec 1998	A
5861268	Tang et al.	Jan 1999	A
5886006	Nikolaides et al.	Mar 1999	A
5939047	Jernberg	Aug 1999	A
5939090	Beaurline et al.	Aug 1999	A
5962479	Chen	Oct 1999	A
5962636	Bachmaier et al.	Oct 1999	A
5977366	Gerster et al.	Nov 1999	A
6028076	Hirota et al.	Feb 2000	A
6039969	Tomai et al.	Mar 2000	A
6057371	Glennon	May 2000	A
6069140	Sessler et al.	May 2000	A
6069149	Nanba et al.	May 2000	A
6071949	Mulshine et al.	Jun 2000	A
6077349	Kikuchi	Jun 2000	A
6083505	Miller et al.	Jul 2000	A
6110929	Gerster et al.	Aug 2000	A
6113918	Johnson et al.	Sep 2000	A
6121323	Merrill	Sep 2000	A
6123957	Jernberg	Sep 2000	A
6126938	Guy et al.	Oct 2000	A
6194388	Krieg et al.	Feb 2001	B1
6194425	Gerster et al.	Feb 2001	B1
6200592	Tomai et al.	Mar 2001	B1
6207646	Krieg et al.	Mar 2001	B1
6239116	Krieg et al.	May 2001	B1
6245776	Skwierczynski et al.	Jun 2001	B1
6294271	Sumita et al.	Sep 2001	B1
6303347	Johnson et al.	Oct 2001	B1
6309623	Weers et al.	Oct 2001	B1
6315985	Wu et al.	Nov 2001	B1
6323200	Gerster et al.	Nov 2001	B1
6329381	Kurimoto et al.	Dec 2001	B1
6331539	Crooks et al.	Dec 2001	B1
6339068	Krieg et al.	Jan 2002	B1
6348462	Gerster et al.	Feb 2002	B1
6365166	Beaurline et al.	Apr 2002	B2
6376501	Isobe et al.	Apr 2002	B1
6376669	Rice et al.	Apr 2002	B1
6387383	Dow et al.	May 2002	B1
6387938	Mizuguchi et al.	May 2002	B1
6406705	Davis et al.	Jun 2002	B1
6426334	Agrawal et al.	Jul 2002	B1
6440992	Gerster et al.	Aug 2002	B1
6451485	James et al.	Sep 2002	B1
6451810	Coleman et al.	Sep 2002	B1
6465654	Gerster et al.	Oct 2002	B2
6476000	Agrawal	Nov 2002	B1
6486168	Skwierczynski et al.	Nov 2002	B1
6486186	Fowler et al.	Nov 2002	B2
6511485	Hirt et al.	Jan 2003	B2
6514985	Gerster et al.	Feb 2003	B1
6518239	Kuo et al.	Feb 2003	B1
6518265	Kato et al.	Feb 2003	B1
6518280	Gerster et al.	Feb 2003	B2
6525028	Johnson et al.	Feb 2003	B1
6525064	Dellaria et al.	Feb 2003	B1
6541485	Crooks et al.	Apr 2003	B1
6545016	Dellaria et al.	Apr 2003	B1
6545017	Dellaria et al.	Apr 2003	B1
6558951	Tomai et al.	May 2003	B1
6573273	Crooks et al.	Jun 2003	B1
6582957	Turner, Jr. et al.	Jun 2003	B1
6610319	Tomai et al.	Aug 2003	B2
6627638	Gerster et al.	Sep 2003	B2
6627639	Stack et al.	Sep 2003	B2
6627640	Gerster et al.	Sep 2003	B2
6630588	Rice et al.	Oct 2003	B2
6638944	Mickelson	Oct 2003	B2
6649172	Johnson	Nov 2003	B2
6656938	Crooks et al.	Dec 2003	B2
6660735	Crooks et al.	Dec 2003	B2
6660747	Crooks et al.	Dec 2003	B2
6664260	Charles et al.	Dec 2003	B2
6664264	Dellaria et al.	Dec 2003	B2
6664265	Crooks et al.	Dec 2003	B2
6667312	Bonk et al.	Dec 2003	B2
6670372	Charles et al.	Dec 2003	B2
6677334	Gerster et al.	Jan 2004	B2
6677347	Crooks et al.	Jan 2004	B2
6677348	Heppner et al.	Jan 2004	B2
6677349	Griesgraber	Jan 2004	B1
6683088	Crooks et al.	Jan 2004	B2
6696076	Tomai et al.	Feb 2004	B2
6696465	Dellaria et al.	Feb 2004	B2
6703402	Gerster et al.	Mar 2004	B2
6706728	Hedenstrom et al.	Mar 2004	B2
6716988	Dellaria et al.	Apr 2004	B2
6720333	Dellaria et al.	Apr 2004	B2
6720334	Dellaria et al.	Apr 2004	B2
6720422	Dellaria et al.	Apr 2004	B2
6743920	Lindstrom et al.	Jun 2004	B2
6756382	Coleman et al.	Jun 2004	B2
6780873	Crooks et al.	Aug 2004	B2
6784188	Crooks et al.	Aug 2004	B2
6790961	Gerster et al.	Sep 2004	B2
6797718	Dellaria et al.	Sep 2004	B2
6800624	Crooks et al.	Oct 2004	B2
6818650	Griesgraber	Nov 2004	B2
6825350	Crooks et al.	Nov 2004	B2
6841678	Merli et al.	Jan 2005	B2
6852861	Merli et al.	Feb 2005	B2
6855217	Suzuki	Feb 2005	B2
6855350	Lu	Feb 2005	B2
6878719	Lindstrom et al.	Apr 2005	B2
6888000	Crooks et al.	May 2005	B2
6894060	Slade	May 2005	B2
6894165	Gerster et al.	May 2005	B2
6897221	Crooks et al.	May 2005	B2
6900016	Venter et al.	May 2005	B1
6903113	Heppner et al.	Jun 2005	B2
6916925	Rice et al.	Jul 2005	B1
6921826	Dellaria et al.	Jul 2005	B2
6924293	Lindstrom	Aug 2005	B2
6943240	Bauer et al.	Sep 2005	B2
6943255	Lindstrom et al.	Sep 2005	B2
6949649	Bonk et al.	Sep 2005	B2
6953804	Dellaria et al.	Oct 2005	B2
6969722	Heppner et al.	Nov 2005	B2
6989389	Heppner et al.	Jan 2006	B2
7030129	Miller et al.	Apr 2006	B2
7030131	Crooks et al.	Apr 2006	B2
7038053	Lindstrom et al.	May 2006	B2
7049439	Crooks et al.	May 2006	B2
7078253	Brunner et al.	Jul 2006	B2
7078523	Crooks et al.	Jul 2006	B2
7091214	Hays et al.	Aug 2006	B2
7098221	Heppner et al.	Aug 2006	B2
7112677	Griesgraber	Sep 2006	B2
7115622	Crooks et al.	Oct 2006	B2
7125890	Dellaria et al.	Oct 2006	B2
7132429	Griesgraber et al.	Nov 2006	B2
7163947	Griesgraber et al.	Jan 2007	B2
7179253	Graham et al.	Feb 2007	B2
7199131	Lindstrom	Apr 2007	B2
7214675	Griesgraber	May 2007	B2
7220758	Dellaria et al.	May 2007	B2
7226928	Mitra et al.	Jun 2007	B2
7276515	Dellaria et al.	Oct 2007	B2
7288550	Dellaria et al.	Oct 2007	B2
7375180	Gorden et al.	May 2008	B2
7387271	Noelle et al.	Jun 2008	B2
7393859	Coleman et al.	Jul 2008	B2
7427629	Kedl et al.	Sep 2008	B2
7544697	Hays et al.	Jun 2009	B2
7598382	Hays et al.	Oct 2009	B2
7612083	Griesgraber	Nov 2009	B2
7648997	Kshirsagar et al.	Jan 2010	B2
20010046968	Zagon et al.	Nov 2001	A1
20020016332	Slade	Feb 2002	A1
20020055517	Smith	May 2002	A1
20020058674	Hedenstrom et al.	May 2002	A1
20020107262	Lindstrom	Aug 2002	A1
20020110840	Tomai et al.	Aug 2002	A1
20020137101	Meyers	Sep 2002	A1
20020173655	Dellaria et al.	Nov 2002	A1
20020193729	Cormier et al.	Dec 2002	A1
20030022302	Lewis et al.	Jan 2003	A1
20030044429	Aderem et al.	Mar 2003	A1
20030082108	Mulshine et al.	May 2003	A1
20030088102	Matsubara et al.	May 2003	A1
20030096835	Crooks et al.	May 2003	A1
20030096998	Gerster et al.	May 2003	A1
20030130299	Crooks et al.	Jul 2003	A1
20030133733	Korhonen	Jul 2003	A1
20030133913	Tomai et al.	Jul 2003	A1
20030139364	Krieg et al.	Jul 2003	A1
20030144283	Coleman et al.	Jul 2003	A1
20030144286	Frenkel et al.	Jul 2003	A1
20030158192	Crooks et al.	Aug 2003	A1
20030161797	Miller et al.	Aug 2003	A1
20030172391	Turner et al.	Sep 2003	A1
20030185835	Braun	Oct 2003	A1
20030187016	Crooks et al.	Oct 2003	A1
20030199461	Averett et al.	Oct 2003	A1
20030199538	Skwierczynski et al.	Oct 2003	A1
20030212092	Heppner et al.	Nov 2003	A1
20030216481	Jia	Nov 2003	A1
20030232074	Lipford et al.	Dec 2003	A1
20030232763	Jia	Dec 2003	A1
20030232852	Lindstrom et al.	Dec 2003	A1
20040010007	Dellaria et al.	Jan 2004	A1
20040014779	Gorden et al.	Jan 2004	A1
20040023870	Dedera et al.	Feb 2004	A1
20040067975	Crooks et al.	Apr 2004	A1
20040072858	Charles et al.	Apr 2004	A1
20040076633	Thomsen et al.	Apr 2004	A1
20040091491	Kedl et al.	May 2004	A1
20040092545	Crooks et al.	May 2004	A1
20040097542	Crooks et al.	May 2004	A1
20040106638	Lindstrom	Jun 2004	A1
20040132079	Gupta et al.	Jul 2004	A1
20040132748	Isobe et al.	Jul 2004	A1
20040132766	Griesgraber	Jul 2004	A1
20040141950	Noelle et al.	Jul 2004	A1
20040147543	Hays et al.	Jul 2004	A1
20040157874	Crooks et al.	Aug 2004	A1
20040162309	Gorden et al.	Aug 2004	A1
20040167157	Masui et al.	Aug 2004	A1
20040171086	Fink et al.	Sep 2004	A1
20040175336	Egging et al.	Sep 2004	A1
20040176367	Griesgraber et al.	Sep 2004	A1
20040180919	Lee et al.	Sep 2004	A1
20040181130	Fox et al.	Sep 2004	A1
20040181211	Elliott et al.	Sep 2004	A1
20040191833	Fink et al.	Sep 2004	A1
20040192585	Fox et al.	Sep 2004	A1
20040197865	Gupta et al.	Oct 2004	A1
20040202720	Wightman et al.	Oct 2004	A1
20040204436	Gerster et al.	Oct 2004	A1
20040214851	Birmachu et al.	Oct 2004	A1
20040258698	Wightman et al.	Dec 2004	A1
20040265351	Miller et al.	Dec 2004	A1
20050009858	Martinez-Colon et al.	Jan 2005	A1
20050032829	Lindstrom et al.	Feb 2005	A1
20050048072	Kedl et al.	Mar 2005	A1
20050054590	Averett	Mar 2005	A1
20050054640	Griesgraber et al.	Mar 2005	A1
20050054665	Miller et al.	Mar 2005	A1
20050059072	Birmachu et al.	Mar 2005	A1
20050070460	Hammerbeck et al.	Mar 2005	A1
20050085500	Gutman et al.	Apr 2005	A1
20050096259	Tomai et al.	May 2005	A1
20050119273	Lipford et al.	Jun 2005	A1
20050136065	Valiante	Jun 2005	A1
20050148620	Crooks et al.	Jul 2005	A1
20050158325	Hammerbeck et al.	Jul 2005	A1
20050165236	Colombo et al.	Jul 2005	A1
20050171072	Tomai et al.	Aug 2005	A1
20050226878	Tomai et al.	Oct 2005	A1
20050234088	Griesgraber	Oct 2005	A1
20050239733	Jurk et al.	Oct 2005	A1
20050239735	Miller et al.	Oct 2005	A1
20050245562	Garcia-Echeverria et al.	Nov 2005	A1
20050267145	Merrill et al.	Dec 2005	A1
20050281813	Dedera et al.	Dec 2005	A1
20060009482	Tomai et al.	Jan 2006	A1
20060100229	Hays et al.	May 2006	A1
20060106052	Crooks et al.	May 2006	A1
20060188913	Krieg et al.	Aug 2006	A1
20070060754	Lindstrom et al.	Mar 2007	A1
20070066639	Kshirsagar et al.	Mar 2007	A1
20070072893	Krepski et al.	Mar 2007	A1
20070099901	Krepski et al.	May 2007	A1
20070155767	Radmer et al.	Jul 2007	A1
20070166384	Zarraga	Jul 2007	A1
20070167476	Kshirsagar et al.	Jul 2007	A1
20070213356	Merrill et al.	Sep 2007	A1
20070219196	Krepski et al.	Sep 2007	A1
20070219228	Niwas et al.	Sep 2007	A1
20070259881	Dellaria et al.	Nov 2007	A1
20070259907	Prince	Nov 2007	A1
20070287725	Miser et al.	Dec 2007	A1
20070292456	Hammerbeck et al.	Dec 2007	A1
20080015184	Kshirsagar et al.	Jan 2008	A1
20080070907	Griesgraber et al.	Mar 2008	A1
20080085895	Griesgraber et al.	Apr 2008	A1
20080114019	Kshirsagar et al.	May 2008	A1
20080119508	Slade et al.	May 2008	A1
20080207674	Stoesz et al.	Aug 2008	A1
20080269192	Griesgraber et al.	Oct 2008	A1
20080306252	Crooks et al.	Dec 2008	A1
20080312434	Lindstrom et al.	Dec 2008	A1
20080318998	Prince et al.	Dec 2008	A1
20090005371	Rice et al.	Jan 2009	A1
20090017076	Miller et al.	Jan 2009	A1
20090018122	Lindstrom et al.	Jan 2009	A1
20090023722	Coleman et al.	Jan 2009	A1
20090029988	Kshirsagar et al.	Jan 2009	A1
20090030030	Bonk et al.	Jan 2009	A1
20090030031	Kshirsagar et al.	Jan 2009	A1
20090042925	Kshirsagar et al.	Feb 2009	A1
20090062272	Bonk et al.	Mar 2009	A1
20090062328	Kshirsagar et al.	Mar 2009	A1
20090069299	Merrill et al.	Mar 2009	A1
20090069314	Kshirsagar et al.	Mar 2009	A1
20090075980	Hays et al.	Mar 2009	A1
20090099161	Rice et al.	Apr 2009	A1
20090105295	Kshirsagar et al.	Apr 2009	A1
20090124611	Hays et al.	May 2009	A1
20090163532	Perman et al.	Jun 2009	A1
20090163533	Hays et al.	Jun 2009	A1
20090176821	Kshirsagar et al.	Jul 2009	A1
20090240055	Krepski et al.	Sep 2009	A1
20090253695	Kshirsagar et al.	Oct 2009	A1
20090270443	Stoermer et al.	Oct 2009	A1
20090318435	Hays et al.	Dec 2009	A1
20100113565	Gorden et al.	May 2010	A1

Number	Date	Country
2004220534	Sep 2004	AU
2004229478	Oct 2004	AU
2004264336	Feb 2005	AU
2004268625	Mar 2005	AU
2002239547	Nov 2006	AU
2044087	Dec 1991	CA
2158996	Oct 1994	CA
1354663	Jun 2002	CN
0 145 340	Jun 1985	EP
0 223 420	May 1987	EP
0 310 950	Apr 1989	EP
0 385 630	Sep 1990	EP
0 389 302	Sep 1990	EP
0 394 026	Oct 1990	EP
0 425 306	May 1991	EP
0 510 260	Oct 1992	EP
0 645 389	Mar 1995	EP
0 778 277	Jun 1997	EP
0 894 797	Feb 1999	EP
1 082 960	Mar 2001	EP
1 097 709	May 2001	EP
1 104 764	Jun 2001	EP
1 145 340	Oct 2001	EP
1 256 582	Nov 2002	EP
1 341 791	Sep 2003	EP
1 495 758	Jan 2005	EP
34479	Mar 1985	HU
210051	Jun 1991	HU
218950	Sep 1995	HU
73534	Dec 1990	IL
53050197	May 1978	JP
63010787	Jan 1988	JP
4066571	Mar 1992	JP
4327587	Nov 1992	JP
5286973	Nov 1993	JP
9-208584	Aug 1997	JP
11-080156	Mar 1999	JP
11-222432	Aug 1999	JP
2000-247884	Sep 2000	JP
545412	Dec 2008	NZ
2076105	Mar 1997	RU
2127273	Mar 1999	RU
2221798	Jan 2004	RU
WO-9106682	May 1991	WO
WO-9206093	Apr 1992	WO
WO-9215581	Sep 1992	WO
WO-9215582	Sep 1992	WO
WO-9305042	Mar 1993	WO
WO-9309119	May 1993	WO
WO-9320847	Oct 1993	WO
WO-9410171	May 1994	WO
WO-9502597	Jan 1995	WO
WO-9502598	Jan 1995	WO
WO-9611199	Apr 1996	WO
WO-9621663	Jul 1996	WO
WO-9748703	Dec 1997	WO
WO-9748704	Dec 1997	WO
WO-9817279	Apr 1998	WO
WO-9830562	Jul 1998	WO
WO-9848805	Nov 1998	WO
WO-9850547	Nov 1998	WO
WO-9854226	Dec 1998	WO
WO-9918105	Apr 1999	WO
WO-9929693	Jun 1999	WO
WO-0006577	Feb 2000	WO
WO-0009506	Feb 2000	WO
WO-0019987	Apr 2000	WO
WO-0040228	Jul 2000	WO
WO-0047719	Aug 2000	WO
WO-0075304	Dec 2000	WO
WO-0076505	Dec 2000	WO
WO-0076518	Dec 2000	WO
WO-0076519	Dec 2000	WO
WO-0134709	May 2001	WO
WO-0151486	Jul 2001	WO
WO-0155439	Aug 2001	WO
WO-0158900	Aug 2001	WO
WO-0174343	Oct 2001	WO
WO-0174821	Oct 2001	WO
WO-0207725	Jan 2002	WO
WO-0222809	Mar 2002	WO
WO-0224225	Mar 2002	WO
WO 0236592	May 2002	WO
WO-0246188	Jun 2002	WO
WO-0246189	Jun 2002	WO
WO-0246190	Jun 2002	WO
WO-0246191	Jun 2002	WO
WO-0246192	Jun 2002	WO
WO-0246193	Jun 2002	WO
WO-0246194	Jun 2002	WO
WO-0246749	Jun 2002	WO
WO-02085905	Oct 2002	WO
WO-02102377	Dec 2002	WO
WO-03008421	Jan 2003	WO
WO-03009852	Feb 2003	WO
WO-03020889	Mar 2003	WO
WO-03043572	May 2003	WO
WO-03045391	Jun 2003	WO
WO-03045494	Jun 2003	WO
WO-03045929	Jun 2003	WO
WO-03050117	Jun 2003	WO
WO-03050118	Jun 2003	WO
WO-03050119	Jun 2003	WO
WO-03050121	Jun 2003	WO
WO-03077944	Sep 2003	WO
WO-03080114	Oct 2003	WO
WO-03086280	Oct 2003	WO
WO-03086350	Oct 2003	WO
WO-03089602	Oct 2003	WO
WO-03097641	Nov 2003	WO
WO-03101949	Dec 2003	WO
WO-03103584	Dec 2003	WO
WO-2004028539	Apr 2004	WO
WO-2004041285	May 2004	WO
WO-2004043913	May 2004	WO
WO-2004053057	Jun 2004	WO
WO-2004053452	Jun 2004	WO
WO-2004058759	Jul 2004	WO
WO-2004071459	Aug 2004	WO
WO-2004075865	Sep 2004	WO
WO-2004080398	Sep 2004	WO
WO-2004091500	Oct 2004	WO
WO-2004096144	Nov 2004	WO
WO-2004110991	Dec 2004	WO
WO-2004110992	Dec 2004	WO
WO-2005003064	Jan 2005	WO
WO-2005003065	Jan 2005	WO
WO-2005016273	Feb 2005	WO
WO-2005016275	Feb 2005	WO
WO 2005018551	Mar 2005	WO
WO 2005018555	Mar 2005	WO
WO 2005018556	Mar 2005	WO
WO 2005020999	Mar 2005	WO
WO-2005023190	Mar 2005	WO
WO-2005025614	Mar 2005	WO
WO-2005029037	Mar 2005	WO
WO 2005032484	Apr 2005	WO
WO-2005041891	May 2005	WO
WO 2005048933	Jun 2005	WO
WO 2005048945	Jun 2005	WO
WO-2005049076	Jun 2005	WO
WO 2005051317	Jun 2005	WO
WO 2005051324	Jun 2005	WO
WO 2005054237	Jun 2005	WO
WO 2005054238	Jun 2005	WO
WO-2005065678	Jul 2005	WO
WO 2005066169	Jul 2005	WO
WO 2005066170	Jul 2005	WO
WO 2005066172	Jul 2005	WO
WO-2005067500	Jul 2005	WO
WO 2005076783	Aug 2005	WO
WO 2005079195	Sep 2005	WO
WO 2005094531	Oct 2005	WO
WO-2005110013	Nov 2005	WO
WO 2005123079	Dec 2005	WO
WO 2005123080	Dec 2005	WO
WO 2006009826	Jan 2006	WO
WO 2006009832	Jan 2006	WO
WO 2006026760	Mar 2006	WO
WO 2006028451	Mar 2006	WO
WO 2006028545	Mar 2006	WO
WO 2006028962	Mar 2006	WO
WO 2006029115	Mar 2006	WO
WO 2006031878	Mar 2006	WO
WO 2006038923	Apr 2006	WO
WO-2006063072	Jun 2006	WO
WO-2006063152	Jun 2006	WO
WO 2006065280	Jun 2006	WO
WO-2006073940	Jul 2006	WO
WO 2006074003	Jul 2006	WO
WO-2006074045	Jul 2006	WO
WO 2006004737	Aug 2006	WO
WO 2006083400	Aug 2006	WO
WO 2006083440	Aug 2006	WO
WO-2006084251	Aug 2006	WO
WO 2006086449	Aug 2006	WO
WO 2006086633	Aug 2006	WO
WO-2006086634	Aug 2006	WO
WO 2006091394	Aug 2006	WO
WO 2006091567	Aug 2006	WO
WO 2006091568	Aug 2006	WO
WO 2006091647	Aug 2006	WO
WO-2006093514	Sep 2006	WO
WO 2006098852	Sep 2006	WO
WO-2006107753	Oct 2006	WO
WO 2006107771	Oct 2006	WO
WO 2006107851	Oct 2006	WO
WO 2006107853	Oct 2006	WO
WO 2006121528	Nov 2006	WO
WO-2006122806	Nov 2006	WO
WO-2007028129	Mar 2007	WO
WO-2007030775	Mar 2007	WO
WO-2007030777	Mar 2007	WO
WO-2007035935	Mar 2007	WO
WO-2007056112	May 2007	WO
WO-2007062043	May 2007	WO
WO-2007075468	Jul 2007	WO
WO-2007079086	Jul 2007	WO
WO-2007079146	Jul 2007	WO
WO-2007079169	Jul 2007	WO
WO-2007079171	Jul 2007	WO
WO-2007079202	Jul 2007	WO
WO-2007079203	Jul 2007	WO
WO-2007092641	Aug 2007	WO
WO-2007106852	Sep 2007	WO
WO-2007106854	Sep 2007	WO
WO-2007120121	Oct 2007	WO
WO-2007143526	Dec 2007	WO
WO-2008008432	Jan 2008	WO
WO-2008030511	Mar 2008	WO
WO-2008036312	Mar 2008	WO
WO-2008045543	Apr 2008	WO